roche finance report hoffmannla roche ltd finance report basel switzerland trademark legally protect wwwrochecom xxx xxxfinance brief key result sale core operate profit margin cer growth sale pharmaceutical diagnostic group change sales mchf mchf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change mchf mchf chf cer net debt capitalisation ebt quity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant currency average rate year end december core result core ep earning share exclude noncore item global restructuring charge amortisation impairment goodwill intangible asset allow transparent assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give therefinance brief roche roche group report strong overall result challenge market core operating profit grow ahead sale core earning share increase constant exchange rate cer swiss franc weak average rate major currency notably dollar japanese yen positive overall impact income statement cash flow express swiss franc sale group sale increase cer billion swiss franc growth swiss franc term pharmaceutical sale growth cer strong growth establish new oncology product actemraroactemra rheumatoid arthritis pegasys virology partially offset continue impact generic competition continue pressure price particularly japan western europe diagnostic sale grow cer ahead market professional diagnostic tissue diagnostic major contributor operate result core operating profit increase cer billion swiss franc growth swiss franc term sale growth productivity improvement cost saving global restructuring plan offset high operating cost investment key market impact price pressure increase competition core operating margin increase percentage point research development expenditure remain broadly stable slight increase cer billion swiss franc core basis strict portfolio prioritisation support development pipeline cost group sale ifrs operating result include noncore item billion swiss franc include billion restructuring pharmaceutical division research development organisation restructure diagnostic division apply science diabete care business nonoperate result net financial expense increase billion swiss franc billion swiss franc low interest expense offset high net foreign exchange loss high loss debt redemption net income ifrs net income increase cer billion swiss franc swiss franc term strong core operating result offset high restructuring charge high effective tax rate core earning share increase constant currency swiss franc cash flow operate free cash flow billion swiss franc cer high operating profit free cash flow billion swiss franc cer repayment debt ahead schedule note bond issue finance genentech transaction repay end financial position net working capital increase cer reflect high level inventory launch growth key product high safety stock level increase demand key market net debt position improve billion swiss franc billion swiss franc credit rating strong moodys standard poor upgrade shareholder return dividend propose increase represent consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr represent combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement summary significant accounting policy ccount receivable perating segment information current asset hugai arketable security financial income financing cost cash cash equivalent ncome taxis ccount payable usiness combination accrue current liability global restructuring plan derivative financial instrument mployee benefit provision contingent liability pension postemployment noncurrent liability benefit ebt employee stock option equity equity attributable roche shareholder compensation plan earning share nonvoting equity property plant equipment security oodwill oncontrolle interest ntangible asset statement cash flow ssociate isk management financial longterm asset elated party nventorie subsidiary associate report roche management internal control financial reporting report statutory auditor consolidated financial statement report independent auditor internal control financial report multiyear overview supplementary information roche security roche hol ding ltd basel financial statement note financial statement appropriation available earning report statutory auditor financial statement financial review roche group result sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf roche group result report growth core operating activity sale core operating profit constant exchange rate core operate margin percentage point sale volume increase notably emerge market china latin america offset pricing pressure market cost sale ratio improve percentage point sale drive continue productivity improvement pharmaceutical division operating cost hold necessary level support future development business notably research development increase slightly portfolio prioritisation support development pipeline strong operating performance partially offset high tax rate responsible increase core ep constant exchange rate operate free cash flow grow billion swiss franc sale half group initiate number major restructuring initiative position business future notably pharmaceutical division research development organisation announcement closure nutley site diagnostic division initiate global restructuring programme apply science diabetes care business area address longterm profitability focus few business product consolidate operation net income ifrs basis increase billion swiss franc swiss franc strong operating result offset large restructuring cost sale pharmaceutical division rise lead growth oncology portfolio sale billion swiss franc key growth driver herceptin mabtherarituxan avastin actemraroactemra zelboraf pegasys key emerge market show growth lead sale growth china diagnostic sale grow expand division lead market position major growth area professional diagnostic tissue diagnostic sale diabetes care apply science decline core operating profit increase pharmaceutical division grow diagnostic division fall division show increase marketing distribution cost drive investment new product key market notably china increase cost factor contribute improve cash collection especially southern europe bad debt expense decrease compare group level profitability pharmaceutical increase percentage point sale growth decrease cost sale productivity improvement portfolio prioritisation research development diagnostic profitability decline percentage point mainly pricing pressure diabetes care business roche group financial review roche finance report operate free cash flow billion swiss franc increase compare reflect continue strong underlying cash generation group operation make necessary investment develop business increase free cash flow billion swiss franc average swiss franc weak compare average rate major currency notably dollar japanese yen overall impact positive income statement cash flow express swiss franc compare result constant exchange rate income statement change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable oche shareholders oncontrolle interest dilute eps chf core result sale royalty operate income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable oche shareholders oncontrolle interest core eps chf roche finance report roche group financial reviewsale sale increase constant exchange rate swiss franc dollar billion swiss franc sale pharmaceutical division rise herceptin mabtherarituxan avastin actemraroactemra zelboraf pegasys grow strongly avastin return growth increase sale positive result partially offset continue decline bonvivaboniva cellcept sale generic erosion follow patent expiry neorecormonepogin competition biosimilar key emerge market sale pharmaceutical grow lead growth china diagnostic division sale billion swiss franc increase constant exchange rate expand lead market position major growth area professional diagnostic represent half division sale grow tissue diagnostic show strong growth diabete care sale decline applied science sale divisional operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operate free cash flow increase cer margin percentage point increase core operating result pharmaceutical division division increase core operate profit constant exchange rate drive growth underlie business increase sale improve gross profit margin contain spend core research development cost remain broadly stable slight increase increase marketing distribution fall general administration diagnostic division core operate profit sale increase offset pricing pressure diabetes care business cost sale increase high rate sale growth pricing impact increase placement cost follow expansion worldwide instal instrument base research development marketing distribution cost keep line sale growth significant growth general administration cost base effect release provision describe division initiate global restructuring plan address longterm profitability apply science diabetes care business area roche group financial review roche finance report global restructuring plan half group initiate major global restructuring plan notably reorganisation research development pharmaceutical division address longterm profitability apply science diabetes care business area global restructuring plan cost incur millions chf pharma pharma diagnostic informatic plan total global restructuring cost mployeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost include closure nutley site associate infrastructure environmental remediation cost include restructure apply science diabetes care business area include operational excellence pharmaceutical diagnostic dalcetrapib pharmaceutical pharmaceutical division research development reorganisation june group announce streamline research development activity pharmaceutical division plan site nutley new jersey closed end reduction workforce approximately people research development activity currently undertake nutley consolidated exist site switzerland germany plan translational clinical research centre alexandria centre life science manhattan result saving global site consolidation relate infrastructure cost bundle support function shift portfolio allow reallocation resource grow number clinical programme cost million swiss franc incur base late estimate cost reorganisation million swiss franc provision severance payment employeerelate cost net estimate pension curtailment gain charge million swiss franc record impairment property plant equipment nutley site addition restructuring cost environmental remediation cost million swiss franc book base initial estimate additional remediation activity need nutley site sell impairment charge intangible asset million swiss franc record result portfolio prioritisation decision link reorganisation diagnostic division apply science diabetes care restructuring initiative announce applied science diabete care business include streamline product portfolio consolidate research development activity increase efficiency marketing distribution operation cost million swiss franc incur relate employee termination site closure cost addition goodwill impairment charge million swiss franc incur writeoff goodwill nimblegen acquisition result decision exit microarray business reorganisation apply science business area million swiss franc impairment intangible asset business area pharmaceutical division global informatic reorganisation cost million swiss franc incur mainly consist severance payment employeerelate cost roche finance report roche group financial reviewother global restructuring plan cost million swiss franc incur previously announce operational excellence programme mainly employeerelate cost sale force restructure initiative pharmaceutical division employeerelate site closure cost diagnostic division site burgdorf switzerland graz austria second quarter pharmaceutical division initiate detailed review follow announcement result second interim analysis dalcetrapib daloutcome phase iii trial subsequent termination daloutcome trial study dalheart programme consequently restructure cost million swiss franc incur consist remain trial cost writeoff inventory property plant equipment additionally million swiss franc expense writeoff previously acquire intangible asset impairment goodwill intangible asset impairment charge goodwill intangible asset million swiss franc million swiss franc respectively approximately half incur global restructuring initiative describe addition unrelated global restructuring plan impairment charge million swiss franc record major element charge million swiss franc follow portfolio prioritisation decision pharmaceutical division relate decision return global right monoclonal antibody antiplgf mab alliance partner charge million swiss franc follow late clinical datum assessment project acquire marcadia acquisition legal environmental settlement addition environmental remediation cost million swiss francs nutley site mention million swiss franc legal environmental cost record unrelated global restructuring plan include estimate additional remediation cost landfill site near grenzach germany previously manufacturing operation close year ago treasury taxation financial income billion swiss franc decrease mainly foreign currency loss devaluationrelated foreign exchange gain occur venezuela financing cost billion swiss franc decrease interest cost low constant exchange rate debt repay core tax expense increase billion swiss franc group effective core tax rate increase compare mainly consequence high percentage core profit contribution come relatively high local tax rate average group rate net income earning share ifrs net income increase diluted eps strong core operating performance offset cost global restructuring plan core basis exclude noncore item global restructuring cost amortisation impairment goodwill intangible asset net income core ep higher drive strong operating performance partially offset high effective tax rate supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result roche group financial review roche finance report financial position change change mchf mchf chf cer pharmaceuticals net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt pension income taxis nonoperate asset net total net asset compare start swiss franc strengthen major currency yearend importantly dollar japanese yen follow intervention swiss national bank start second half swiss franc stable euro pharmaceutical division net work capital increase constant exchange rate inventory increase mainly inventory building support recent upcoming product launch ensure supply increase sale demand meet business expansion emerge market receivables increase impact continue sale growth emerge market partly offset strong collection outstanding receivable notably southern europe payable higher previous year increase accrue liability sale relate chargeback employee incentive accrue royalty longterm net operating asset decrease mainly impact global restructuring plan low intangible asset diagnostic net work capital decrease main driver decrease receivable strong collection factor initiative southern european country offset high inventory level product launch high safety stock increase market demand china decrease payable longterm net operating asset decrease intangible asset decrease additional provision restructuring cost create decrease net debt position mainly free cash flow billion swiss franc net pension liability increase billion swiss franc continue low interest rate increase discount define benefit obligation net tax asset increase mainly defer tax effect increase net pension liability nonoperate net asset decrease decrease interest payable free cash flow change change mchf mchf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay dividend pay free cash flow roche finance report roche group financial reviewthe group operate free cash flow billion swiss franc increase core operating profit constant exchange rate feed increase operate free cash flow cash generation pharmaceutical division increase billion swiss franc strong operating result partially offset increase net work capital increase inventory holding recently launch product additional capital expenditure property plant equipment diagnostic operate free cash flow increase improve collection trade receivables factoring initiative southern european country free cash flow show increase billion swiss franc billion swiss franc primarily billion swiss franc increase operate free cash flow partially offset high tax payment increase annual dividend pharmaceutical division operating result pharmaceutical division operating result change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core ep roche group financial review roche finance report sale overview pharmaceutical division sale therapeutic area change sale sale therapeutic area mchf mchf cer oncology virology inflammationautoimmunetransplantation metabolismbone ophthalmology respiratory disease cardiovascular disease renal anemia central nervous system infectious disease therapeutic area total sale pharmaceutical division sale increase constant exchange rate mainly continue strength oncology portfolio grow division benefit strong growth china brazil growth key product offset negative impact pricing pressure expect decrease sale medicine loss patent exclusivity competition sale growth primarily drive product herceptin mabtherarituxan avastin actemraroactemra zelboraf pegasys product represent portfolio generate billion swiss franc additional sale growth partly offset low sale bonvivaboniva neorecormonepogin lucentis cellcept tamiflu sale increase mainly strong influenza season oncology continue account majority division sale continue growth herceptin mabthera rituxan return growth avastin recently launch zelboraf significant growth contributor virology sale grew benefit continued growth pegasys high tamiflu sale japan sale inflammationautoimmunetransplantation increase continue strong uptake actemraroactemra growth mabtherarituxan rheumatoid arthritis compensating negative impact continue generic erosion cellcept roche finance report roche group financial reviewproduct sale pharmaceutical division sale change sale sale mchf mchf cer oncology herceptin avastin mabtherarituxan xeloda tarceva neutrogin zelboraf neorecormonepogin total oncology virology pegasys valcytecymevene tamiflu total virology inflammationautoimmunetransplantation mabtherarituxan cellcept actemraroactemra total inflammationautoimmune transplantation metabolismbone bonvivaboniva nutropin evista xenical total metabolismbone ophthalmology lucentis total ophthalmology respiratory disease xolair pulmozyme total respiratory disease roche group financial review roche finance report pharmaceutical division sale continue change sale sale mchf mchf cer cardiovascular disease activasetnkase total cardiovascular disease renal anemia neorecormonepogin mircera total renal anemia central nervous system madopar total central nervous system infectious disease rocephin total infectious disease therapeutic area total sale total mabtherarituxan sale million swiss franc million swiss franc split oncology inflammationautoimmune transplantation franchise total neorecormonepogin sale million swiss franc million swiss franc split renal anemia oncology franchise mabtherarituxan change sale sale mchf mchf cer united states western europe japan international total sale mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis sale growth oncology segment drive strong uptake firstline maintenance treatment follicular lymphoma type nhl firstline relapsedrefractory cll western europe sale billion swiss franc increase sale western europe rise sale growth international region include key emerge market russia china mainly uptake nhl indication increase treatment share sale grow despite mandatory price cut market sale franchise billion swiss franc increase constant currency continue positive impact increase use patient inadequate response treatment tumour necrosis factor inhibitor roche finance report roche group financial reviewherceptin change sale sale mchf mchf cer united states western europe japan international total sale herceptin herpositive breast cancer herpositive metastatic advanced stomach cancer sale grow region particularly international region sale grow billion swiss franc demand especially strong cemai central eastern europe middle east africa central asia indian subcontinent latin america region sale billion swiss franc increase largely continued uptake stomach cancer increase availability patient result closure large trial positive breast cancer positive impact ongoing effort improve quality testing believe contribute performance testing key growth driver western europe herceptin group lead product sale billion swiss franc increase global growth programme help improve access emerge market japanese sale drive continued uptake stomach cancer indication avastin change sale sale mchf mchf cer united states western europe japan international total sale avastin advance colorectal breast lung kidney ovarian cancer relapse glioblastoma type brain tumour global sale grow mainly increase use establish indication colorectal lung breast cancer successful launch newly diagnose advanced ovarian cancer western europe avastin receive new approval fourth quarter treatment recurrent ovarian cancer combination standard chemotherapy colorectal cancer treatment continue firstline avastin progression combination secondline chemotherapy overall avastin sales united states billion swiss francs international region growth lead cemai latin america asiapacific sub region growth japan use breast cancer colorectal cancer lung cancer growth western europe use ovarian cancer pegasy change sale sale mchf mchf cer united states western europe japan international total sale pegasys hepatitis sale increase billion swiss franc mainly continued demand pegasys triplecombination therapy directacting hepatitis antiviral ribavirin sale grow western europe sale growth slow second half year follow initial surge leading pegylate interferon pegasys establish key component triplecombination treatment regimen expand market share pegasys prefille pen proclick launch key market make administration medicine convenient roche group financial review roche finance report xeloda change sale sale mchf mchf cer united states western europe japan international total sale xeloda colorectal stomach breast cancer sale increase billion swiss franc growth drive primarily strong demand china japan increase sale partly shortage certain alternative cancer medicine sale western europe impact governmentmandate price cut key market lucentis change sale sale mchf mchf cer united states total sale lucentis wet agerelate macular degeneration wamd macular edema follow central retinal vein occlusion crvo diabetic macular edema dme sale decline billion swiss franc entry competitor drug treat wamd crvo recent launch lucentis treat dme track uptake partly offsetting decline wamd crvo roche file supplemental biologic license application sbla pro nata prn dose wamd approve allow promotion lessthanmonthly dose tarceva change sale sale mchf mchf cer united states western europe japan international total sale tarceva advanced nonsmall cell lung nsclc pancreatic cancer sale rise growth brazil china japan offsetting decline western europe attribute short treatment duration slight decrease patient share secondline nsclc western european sale stabilise fourth quarter regulatory filing submit approval tarceva firstline epidermal growth factor receptor egfr mutationpositive nsclc china submission grant priority review fda decision expect second quarter roche finance report roche group financial reviewcellcept change sale sale mchf mchf cer united states western europe japan international total sale cellcept prevention solid organ transplant rejection sale decline continued generic erosion western europe follow patent expiry respectively sale country international region negatively affect price pressure increase use generic sale grow china continue growth japan reflect position cellcept standard care approve indication actemraroactemra change sale sale mchf mchf cer united states western europe japan international total sale actemraroactemra rheumatoid arthritis systemic juvenile idiopathic arthritis sale continue grow strongly approve indication region japan volume growth offset government price cut sale increase particularly western europe actemraroactemra continue gain market share marketing reimbursement approval additional country continue expand patient access actemraroactemra physician increasingly actemraroactemra prefer drug monotherapy rheumatoid arthritis follow positive result adacta trial show superiority adalimumab set neorecormonepogin change sale sale mchf mchf cer united states western europe japan international total sale neorecormonepogin anemiarenal anemia highly competitive market group overall market share anemia franchise include mircera slightly year combine sale roche neorecormon chugais epogin epoetin beta decline western europe international region sale lower increase biosimilar competition market decline cancerrelate anemia segment competitive pressure low reimbursement price result reduce sale epogin japan sustain decline sale neorecormon epogin partly offset growth sale longeracte erythropoiesisstimulate agent mircera rise million swiss franc growth increase number patient switch start treatment mircera place neorecormonepogin strong contribution high mircera sale come japan product launch july roche group financial review roche finance report bonvivaboniva change sale sale mchf mchf cer united states western europe japan international total sale bonvivaboniva osteoporosis significant decrease reflect fall market demand entry generic market sale western europe lower continue impact generic market pricing reimbursement issue growth asiapacific sub region lead south korea offset low sale rest international region product competitor clinical study tamiflu change sale sale mchf mchf cer united states western europe japan international total sale tamiflu influenza sale increase mainly sale seasonal use quarter year follow strong widespread influenza season sale high japan partly offset low annual sale pandemic stockpile primarily relate replacement expire pandemic stockpile zelboraf change sale sale mchf mchf cer united states western europe japan international total sale zelboraf braf vemutationpositive metastatic melanoma food drug administration fda approve zelboraf august fda simultaneously approve roche diagnostic cobas braf mutation test companion diagnostic identify patient treatment zelboraf appropriate zelboraf approve country sale drive continued uptake reflect high unmet medical need metastatic melanoma strong uptake western europe follow approval start roche finance report roche group financial reviewperjeta change sale sale mchf mchf cer united states western europe japan international total sale perjeta firstline herpositive metastatic breast cancer perjeta treatment combination alongside herceptin chemotherapy gain approval switzerland mexico adoption perjeta line expectation majority physician treat type breast cancer prescribe perjeta pharmaceutical division sale region change sale sale region mchf mchf cer united states western europe japan international emai atin america siapacific ther region total sale central eastern europe middle east africa central asia indian subcontinent united states sale grow dollar term lead product oncology medicine mabtherarituxan avastin herceptin sale billion swiss franc billion swiss franc billion swiss franc respectively pegasys activasetnkase actemraroactemra zelboraf xeloda boost growth compensate expect decline bonvivaboniva lucentis cellcept sale tamiflu increase positive impact sale growth approximately percentage point western europe sale decrease constant currency mainly generic competition bonvivaboniva cellcept price pressure government austerity measure budget constraint high demand oncology product avastin mabtherarituxan herceptin account total sale billion swiss franc launch zelboraf successful uptake actemraroactemra offset price pressure sale mircera neorecormon highly competitive renal anemia market low japan sale grow japanese yen term achieve spite government price cut negative impact sale approximately percentage point major growth driver mircera avastin mabtherarituxan sale rise tamiflu sale sale epogin fall mainly patient treatment switch mircera roche group financial review roche finance report international sale rise drive strong growth latin america asiapacific cemai growth latin america mainly oncology product particular herceptin avastin mabtherarituxan sale growth particularly strong brazil argentina high demand mabtherarituxan herceptin xeloda lift sale asiapacific china remain main driver region overall sale growth sale growth cemai mainly increase herceptin mabtherarituxan avastin sale drive tender sale algeria russia sales mexico decrease biosimilar competition mabtherarituxan total sale key emerge market grow pharmaceutical division sale lead emerge market change cer sale sale country mchf mchf total brazil china india mexico russia south korea turkey total sale operating result pharmaceutical division royalty operating income change mchf mchf cer royalty income income outlicense agreement income disposal product total ifrs core basis constant currency increase high income royalty product disposal increase royalty income high lucentis royalty new royalty income eylea soliris sale significant disposal income come disposal rocaltrol ampoule japan rights ostac vesanoid rohypnol certain market increase partly offset low income outlicense agreement pharmaceutical division cost sale change mchf mchf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset east japan earthquake total ifrs basis roche finance report roche group financial reviewcore cost decrease constant exchange rate low manufacturing cost royalty expense percentage sale cost sale decline decrease manufacturing cost good sell period cost mainly productivity improvement product mix effect royalty expense low drive decline royalty expense relate sale bonvivaboniva cellcept royalty expense relate rituxan arbitration expense collaboration profitshare agreement increase mainly drive high copromotion expense high sale mabtherarituxan tarceva xolair global restructuring cost relate writeoff property plant equipment manufacturing cost relate production network rationalisation dalcetrapib trial termination pharmaceutical division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plan east japan earthquake total ifrs basis core cost increase constant exchange rate percentage sale cost fall sale marketing effort focusse drive growth emerge market oncology portfolio include extension avastin ovarian cancer indication new pegasys triplecombination therapy product launch zelboraf perjeta erivedge increase partly initiative assist patient access healthcare significantly low cost incur bad debt expense compare global restructuring cost primarily relate sale force restructure initiative pharmaceutical division research development change mchf mchf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase constant exchange rate research development cost percentage sale low compare increase investment central nervous system rampup studies bitopertin ocrelizumab increase number programme alzheimer disease partially offset low life cycle investment inflammation oncology decision discontinue inflammation research nutley discontinuation avastin adjuvant breast cancer study addition pharmaceutical division spend million swiss franc inlicense pipeline compound technology capitalise intangible asset total division spend billion swiss franc internal purchase research development inlicense alliance deal impairment intangible asset include million swiss franc decision stop development activity dalcetrapib million swiss franc return global right monoclonal antibody antiplgf mab alliance partner million swiss franc late clinical datum assessment project acquire marcadia acquisition addition million swiss franc impairment charge arise result portfolio prioritisation decision follow recent clinical data global restructuring cost include million swiss franc employeerelate cost million swiss franc property plant equipment impairment relate closure nutley site million swiss franc follow dalcetrapib trial termination consist provision remain trial cost writeoff inventory restructure cost million swiss franc mainly relate site closure cost result operational excellence programme roche group financial review roche finance report pharmaceutical division general administration change mchf mchf cer administration restructuring expense gain loss disposal property plant equipment business taxis general item general administration core basis global restructuring plan alliance business combination legal environmental settlement east japan earthquake total ifrs basis core cost decrease constant exchange rate general administration expense percentage sale decrease percentage point administration cost decrease strict cost containment organisational shift corporate function business taxis increase mainly drive favourable tax credit global restructuring cost relate site closure cost nutley mainly impairment property plant equipment division global informatic restructure programme release provision contingent consideration marcadia acquisition result net income alliance business combination cost roche pharmaceutical chugai subdivisional operating result pharmaceutical subdivisional operating result million chf roche pharmaceutical pharmaceutical chugai division sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale pharmaceutical division total core operating profit operating profit include elimination million swiss franc million swiss franc unrealise intercompany profit roche pharmaceutical chugai sale increase subdivision constant currency sale core operating profit roche pharmaceutical increase significantly sale gross profit grow operating expense sale chugai grow chugai core operating profit increase despite low gross margin product mix effect growth core operating margin strict cost containment operating expense roche finance report roche group financial reviewfinancial position pharmaceutical division net operating asset movement movement change change transactions cta mchf mchf chf cer mchf mchf receivables inventory payable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give consolidated financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start swiss franc strengthen major currency yearend importantly dollar japanese yen follow intervention swiss national bank start second half swiss franc stable euro net work capital increase constant exchange rate mainly increase inventory balance sheet value inventory increase mainly inventory building support recent launch continue approval new product zelboraf perjeta erivedge preparation upcoming launch tdm mabthera subcutaneous formulation high inventory level drive need ensure supply increase sale demand business expansion emerge market receivables increase sale growth particular timing strong tamiflu sale year end continue growth business china latin america cemai addition royalty receivables increase high lucentis product royalty effect partly offset strong collection outstanding receivables southern european country payable increase mainly increase accrue liability sale relate chargeback employee incentive accrue royalty longterm net operating asset decrease constant exchange rate mainly impact global restructuring programme impairment intangible asset significant majority record half impairment property plant equipment respect nutley site closure provision employeerelate cost nutley site closure global informatic reorganisation intangible decrease mainly impairment respect dalcetrapib portfolio prioritisation decision monoclonal antibody antiplgf mab impairment project acquire marcadia acquisition impairment charge relate portfolio prioritisation clinical datum roche group financial review roche finance report free cash flow pharmaceutical division operate free cash flow change mchf mchf cer operating profit depreciation amortisation impairment rovision equity compensation plan ther operating profit cash adjustment operate profit net operating cash adjustment increase decrease net work capital eceivable nventorie ayable total increase decrease net working capital investment property plant equipment investment intangible asset total investment operate free cash flow sale detail breakdown provide pharmaceutical division operate free cash flow increase billion swiss franc increase cash generation underlie business partly offset increase net work capital high investment property plant equipment investment include continue site development plan switzerland china construction new production research development facility chugai enhancement expansion production distribution facility switzerland include advanced technology quality control laboratory receivables increase low level cash invest inventory increase launch prelaunch preparation new product ensure supply continue sale growth key growth market asiapacific especially china latin america increase cash outflow equity compensation plan increase roche share price lead increase level exercise employee stock option roche finance report roche group financial reviewdiagnostic division operating result diagnostic division operating result change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core ep sale diagnostic division sale continue increase ahead vitro diagnostic ivd global market growth constant exchange rate professional diagnostic sale growth main growth contributor lead immunodiagnostic business tissue diagnostic sale grew drive advanced stain business business area grow substantially ahead respective market diabetes care sale decrease mainly reimbursement change europe difficult market condition sale molecular diagnostic increase lead blood screening business hcv monitor apply science sale decrease increase competition sequence slowdown public research funding diagnostic division sale business area change sale sale business area mchf mchf cer professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic total sale roche group financial review roche finance report professional diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale professional diagnostic sale grow double rate global market business area strengthen leading position professional diagnostic market include ivd product clinical laboratory near patient testing primary growth driver immunoassay business roche diagnostic enjoy competitive advantage menu different test broad industry instrument series clinical chemistry solution laboratory second large business see continue demand instrument placement area increase strong demand emerge market increase supply partner hitachi high technology effect east japan earthquake point care business growth drive coagulation monitoring device sale growth market regional view growth mainly come emerge market lead asiapacific region particularly china latin america region professional diagnostic grow ahead market emea europe middle east africa north america particularly increase market penetration north america support number key launch business strengthen menu test launch immunoassay market include vitamin vitamin test see strong market uptake worldwide million test month launch professional diagnostic introduce system near patient testing hospital physicians office cobas blood gas accuchek inform blood glucose launch cobas blood lipidglucose launch new system cobas new preanalytic system automate preparatory step laboratory launch diabetes care change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale diabete care sale decline reimbursement cut blood glucose monitoring supply major european market include germany france poland intensify pressure price increase competition lowcost provider particularly roche diabete care launch new accuchek portfolio overall sale decline north america rest world growth drive latin america blood glucose monitoring segment decline year sale insulin delivery system mainly increase market uptake flexlink infusion system business introduce product show promise market uptake blood glucose monitoring system accuchek nano smartview april meterpump combination accuchek combo system october diabetes care continue launch nextgeneration accuchek mobile system japan available country grow roche finance report roche group financial reviewin july diabete care business unit initiate restructure secure longterm profitability measure take research development marketing distribution manufacturing activity business reallocate investment continuous glucose monitor insulin pump expect good market potential differentiate product molecular diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale molecular diagnostic roche molecular diagnostic retain leadership position global molecular diagnostic market hold global market sale growth drive blood screen business hpv cervical cancer screen microbiology business virology testing lead demand hcv monitor regionally growth drive north america primarily hcv monitor hpv testing emea growth blood screen particularly middle east partly offset low virology sale price pressure rest world asiapacific particularly china perform cobas hpv test cervical cancer screening continue positive uptake new contract sign business area expand instrument portfolio preanalytical system launch new nextgeneration test chlamydiagonorrhoea cytomegalovirus hiv new internal external programme start development companion diagnostic add close ongoing collaboration apply science change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale apply science sale decline primarily affect subdue public research funding increase competition gene sequence main sale decline genomics sale sequence microarray low partly offset growth apply science market lead business qpcrnap instrument reagent detection quantification purification nucleic acid custom biotech raw material reagent analytic system healthcare industry increase respectively rest world increase qpcrnap custom biotech lead growth drive latin america june onwards restructure initiative apply science consolidate product segment focus great market potential consequence streamline cellular analysis portfolio exit nimblegen microarray business keep nimblegen sequence capture product line close site reykjavik iceland roche group financial review roche finance report roche apply science continue invest sequence focus area fourth quarter launch new software flx sequence system enhance longread performance introduce sequence capture product start collaboration pss automate emulsion pcr instrument improve sequence workflow business expand custom biotech qpcr portfolio new bioprocess analyser cedex bio biopharmaceutical manufacturing lightcycler qpcr instrument lightcycler see positive uptake close instrument sell month tissue diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale tissue diagnostic sale grow substantially ahead market expand business market leadership position tissuebase cancer diagnostic region north america sales drive instrument placement reagent growth new instrument launch partially offset recent change reimbursement code college american pathologist guideline reduce use negative reagent control roche tissue diagnostic sale growth region reflect increase market penetration rise demand automate tissue diagnostic solution particularly emerge market advance stain system reagent pathology lab detect protein gene tissue sample remain primary growth driver sale increase increase reagent sale placement benchmark series instrument support companion diagnostic business double revenue research diagnostic biomarker product development work partner pharmaceutical industry business initiate new companion diagnostic project partner roche tissue diagnostic launch benchmark special stain platform ventana iscan scanner positive market uptake accounting placement business expand advanced staining menu new immunohistochemistry ihc reagent include test lung pancreatic prostate cancer alk anaplastic lymphoma kinase ihc key companion diagnostic launch october parallel pfizer crizotinib select patient likely benefit lung cancer drug diagnostic division sale region change sale sale region mchf mchf cer europe middle east africa emea north america asiapacific latin america japan total sale divisional sale growth primarily drive asiapacific latin america region professional diagnostic continue main growth driver substantial increase diabetes care latin america north america see growth clinical laboratory business professional tissue molecular diagnostic creation growth momentum launch major product japan sale grow time rate market drive professional diagnostic emea region austerity measure price pressure feel major european market particularly impact diabete care business professional tissue diagnostic continue grow sale gain market share roche finance report roche group financial reviewdiagnostic division sale lead emerge market change sale sale country mchf mchf cer brazil china india mexico russia south korea turkey total sale sale growth emerge market lead china substantial contribution brazil india russia growth china drive government continue effort improve healthcare system roche diagnostic investment strengthen market presence expand customer base large city hospital growth brazil come continue success major public private tender laboratory solution india major public contract diabetes care growth laboratory business operating result diagnostic division royalty operating income change mchf mchf cer royalty income income outlicense agreement income disposal product total ifrs core basis royalty operating income increase constant exchange rate mainly result royalty payment service royalty growth molecular diagnostic receipt royalty payment diabete care income outlicense agreement decrease upfront onetime payment receive diagnostic division cost sale change mchf mchf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis roche group financial review roche finance report cost sale increase constant exchange rate core basis primarily increase manufacturing cost good sell period cost previous cost reduction initiative continue positive impact effect offset increase period cost drive high depreciation placement installation cost new instrument manufacture cost good sell increase change product mix increase overall instal instrument base instrument placement clinical chemistry immunology business drive strong customer demand partly installation instrument source hitachi high technology subject supply disruption follow east japan earthquake march increase royalty expense high sale product inlicense intellectual property overall cost growth core basis sale growth result high cost sale ratio global restructuring cost incur mainly cost relate closure graz burgdorf site reorganisation apply science diabete care business amortisation product intangible decrease intangible asset fully amortise diagnostic division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis increase constant exchange rate core basis mainly reflect high cost professional molecular diagnostic drive sale force increase china factoring cost relate reduction outstanding trade receivables southern europe division core basis marketing distribution cost percentage sale remain global restructuring cost incur mainly reorganisation apply science business diagnostic division research development change mchf mchf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase constant exchange rate drive development new immunoassay test professional diagnostic cobas platform molecular diagnostic instrument tissue diagnostic increase partially offset cost saving apply science diabetes care percentage sale research development cost stable global restructuring cost mainly cost relate operational excellence programme reorganisation diabetes care business roche finance report roche group financial reviewdiagnostics division general administration change mchf mchf cer administration restructuring expense gain loss disposal property plant equipment general item general administration core basis global restructuring plan impairment intangible asset alliance business combination legal environmental settlement total ifrs basis cost increase constant exchange rate core basis cost increase administration mainly drive investment efficiency initiative consist cost formation new sale distribution entity cost general item increase compare base effect income release provision royalty percentage sale cost increase percentage point global restructuring cost mainly employeerelate cost arise graz transfer small extent apply science business area addition goodwill impairment charge million swiss franc incur writeoff goodwill nimblegen acquisition result decision exit microarray business reorganisation apply science business area financial position diagnostic division net operating asset movement movement change change transactions cta mchf mchf chf cer mchf mchf receivables inventory payable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give consolidated financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start swiss franc strengthen major currency yearend importantly dollar japanese yen follow intervention swiss national bank start second half swiss franc stable euro roche group financial review roche finance report net work capital net working capital decrease constant exchange rate increase inventory decrease payable offset reduction receivables inventory increase launch growth key product professional diagnostic tissue diagnostic high safety stock level asia pacific mainly south korea china vietnam increase market demand establishment middleeast hub main factor decrease receivables strong collection factor initiative southern european country region north america reduction receivables ratio compare payable decrease compare end low accrual low trade payable longterm net operating asset decrease constant exchange rate decrease intangible asset nimblegen goodwill impairment increase provision mainly global restructuring plan property plant equipment increase addition especially high instrument placement china partially offset depreciation free cash flow diagnostic division operate free cash flow change mchf mchf cer operating profit depreciation amortisation impairment rovision equity compensation plan ther operating profit cash adjustment operate profit net operating cash adjustment increase decrease net work capital eceivable nventorie ayable total increase decrease net working capital investment property plant equipment investment intangible asset total investment operate free cash flow sale detail breakdown provide operate free cash flow diagnostic division increase constant exchange rate despite decline operating profit primarily lower increase net working capital compare strong collection trade receivables cash receive factoring initiative result decrease receivables high inventory level result launch growth key product professional diagnostic tissue diagnostic high safety stock level asia pacific mainly south korea china vietnam increase market demand establishment middleeast hub payable decrease low accrual low trade payable capital expenditure property plant equipment increase mainly drive investment china total operate free cash flow margin increase percentage point roche finance report roche group financial reviewcorporate operating result corporate operating result summary change mchf mchf cer administration gain loss divestment subsidiary general item general administration cost core basis global restructuring plan alliance business combination legal environmental settlement total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow page definition core result core eps general administration cost increase constant exchange rate result shift certain function pharmaceutical diagnostic division corporate increase human resource informatic cost initiative total cost ifrs basis grow increase environmental provision million swiss franc initial estimate cost additional remediation activity need nutley site prior sell environmental cost estimate additional remediation cost landfill site near grenzach germany previously manufacturing operation close year ago detail matter give note consolidated financial statement corporate operating free cash flow show increase net outflow drive high administration expense describe roche group financial review roche finance report foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer swiss francs change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit exchange rate swiss franc december average december average usd eur jpy average swiss franc weak compare average rate currency include dollar japanese yen strong notably euro brazilian real overall impact positive income statement cash flow express swiss franc compare result constant exchange rate sale development result positive impact percentage point equivalent billion swiss franc translate swiss franc currency translation exposure operating profit mitigate group majority cost base locate outside switzerland core operating profit increase swiss franc compare increase constant exchange rate positive impact percentage point equivalent billion swiss franc sensitivity group sale core operating profit movement average foreign currency exchange rate swiss franc show table currency sensitivity impact rise average exchange rate sale core operating profit versus swiss franc mchf mchf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany obviously large majority chugais cost denominate japanese yen roche finance report roche group financial reviewtreasury taxation result treasury taxation result change change mchf mchf chf cer ifrs result operate profit associate financial income financing cost profit taxis income taxis net income attributable oche shareholders oncontrolle interest core result operate profit associate financial income financing cost profit taxis income taxis net income attributable oche shareholders oncontrolle interest financial position treasury taxation net debt pension income taxis financial longterm asset derivative net collateral net interest payable nonoperate asset net total net asset liability free cash flow treasury taxation treasury activity taxis pay dividend pay total page definition core result core ep financial income financial income million swiss franc decrease compare interest income income debt security million swiss franc decrease low prevailing interest rate net foreign exchange result reflect hedging cost loss million swiss franc compare gain million swiss franc net income equity security million swiss franc expect return pension plan asset million swiss franc broadly line analysis financial income give note consolidated financial statement roche group financial review roche finance report financing cost finance cost million swiss franc decrease compare main driver decrease interest expense reflect continue repayment debt incur finance genentech transaction financing cost include million swiss franc loss combine repurchase million euro note march million euro note march exercise group option early redemption billion dollar note march comparative period contain million swiss franc loss early redemption debt interest cost pension plan remain largely stable million swiss franc analysis financing cost give note consolidated financial statement income taxis group effective core tax rate increase percentage point main reason increase effective tax rate high percentage core profit contribution relatively high local tax rate average group rate tax benefit million swiss franc record noncore item describe compare tax benefit million swiss franc increase primarily high tax benefit result global restructuring plan include intangible asset impairment legal environmental cost compare partially offset tax effect cost result east japan earthquake detail group income tax position give note consolidated financial statement analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf group effective tax rate core basis global restructuring plan intangible asset group effective tax rate ifrs basis financial position decrease net debt position increase operate free cash flow offset high tax payment increase annual dividend fully describe net debt section increase net pension liability reflect fall interest rate lead discount define benefit obligation high net tax asset increase mainly defer tax effect increase net pension liability net derivative position increase net asset billion swiss franc mainly high valuation crosscurrency swap follow strong euro compare dollar interest payable relate bond note coupon payment date march september decline ongoing debt redemption december group hold financial longterm asset market value billion swiss franc consist holding biotechnology company acquire context licensing transaction scientific collaboration free cash flow cash outflow treasury activity remain stable billion swiss franc total taxis pay billion swiss franc increase constant exchange rate high tax payment united states chugai settlement certain outstanding tax position total dividend pay billion swiss franc increase billion swiss franc compare reflect increase roche group dividend roche finance report roche group financial reviewcash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow millions chf pharmaceutical diagnostic corporate group operate profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operating profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operate free cash flow increase constant exchange rate billion swiss franc mainly continue growth underlie operating business show increase core operating profit pharmaceutical strong operating result partially offset increase net work capital high investment property plant equipment diagnostic operate free cash flow increase significantly improved collection trade receivables factoring initiative southern european country cash outflow treasury activity remain stable billion swiss franc total taxis pay billion swiss franc increase high tax payment united states chugai settlement certain outstanding tax position total dividend pay high increase annual roche group dividend free cash flow billion swiss franc billion swiss franc high increase growth operate free cash flow partly offset high tax dividend payment roche group financial review roche finance report net debt million chf december cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow transaction equity instrument business combination net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt period december cash cash equivalent marketable security longterm debt shortterm debt net debt end period net debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen pound sterling total dollardenominate debt include bond note denominate euros swiss franc pound sterling swap dollar financial statement economic characteristic equivalent dollardenominate bond note net debt position group december billion swiss franc decrease billion swiss franc december decrease net debt mainly free cash flow billion swiss franc describe issue debt finance genentech transaction group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar total exposure hedge issuance bond note approximately billion swiss franc collateral agreement enter derivative counterpartie mitigate counterparty risk cash collateral billion swiss franc deliver roche increase cash collateral balance billion swiss franc start year billion swiss franc december collateral balance relation hedge nonus dollardenominate bond note mainly sensitive foreign exchange rate dollar euro pound sterling currently collateral balance move approximately million dollar foreign exchange rate simultaneously collateral volatility decrease million dollars movement foreign exchange rate mid significant portion nonus dollardenominate bond note repay time roche finance report roche group financial reviewthe redemption repurchase bond note issuance new bond note describe note consolidated financial statement direct impact liquid fund material impact net debt position detail group marketable security cash debt position give note consolidated financial statement pension postemployment benefit postemployment benefit plan classify define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan million swiss franc million swiss franc plan classify define benefit plan group potential obligation minor relatively remote possibility arise fund asset management group define benefit plan oversee corporate level plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource fund status balance sheet position mchf mchf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status unrecognise past service cost limit asset recognition reimbursement right net recognise asset liability funding status overall funding status ifrs basis group define benefit plan decrease compare start year decrease came mainly increase define benefit obligation arise fall discount rate comparison end plan asset increase company contribution increase million swiss franc compare million swiss franc group continues closely monitor fund status major pension fund addition cash injection group initiate plan change local pension plan example major pension fund remove early retirement incentive group continue introduce flexible retirement model well accommodate diverse need age workforce roche group financial review roche finance report expense record income statement total pension expense relate group define benefit plan million swiss franc compare million swiss franc decrease primarily high curtailment gain million swiss franc relate nutley restructuring compare million swiss franc curtailment gain base revise actuarial assumption end total pension expense expect approximately million swiss franc high increase mainly drive application ia revise increase net interest cost pension approximately million swiss franc increase approximately million swiss franc current service cost drive fall discount rate estimate pension expense include curtailment past service effect arise year detail group pension postemployment benefit give note consolidated financial statement roche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group healthcare company total shareholder return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group swiss franc term constant exchange rate share price healthcare outperform sector despite continue pressure healthcare price sovereign debt issue europe usa good roche news flow reward relatively strong share price performance peer group abbott laboratories amgen astella astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer roche sanofiaventis takeda total shareholder return development dec march june sept dec roche share roche nonvoting equity security peer set index roche finance report roche group financial reviewpropose dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting consecutive increase dividend dividend proposal approve shareholder dividend payment total share nonvoting equity security billion swiss franc billion swiss franc result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page finance report information share nonvoting equity security change chf chf chf basic eps dilute eps core eps equity attributable roche shareholder share dividend share detail refer note consolidated financial statement page finance report payout ratio calculate dividend share divide core earning share roche group financial review roche finance report debt finance genentech transaction group issue bond note equivalent billion swiss franc february march debt raise early repay december include redemption billion swiss francdenominate note date march billion euro note originally march repurchase march follow tender offer billion euro note originally march repurchase november follow tender offer billion euro note originally march repurchase november follow tender offer furthermore december group exercise option early redemption billion dollar note march note repay march group issue total billion swiss franc note issue billion euro note bond coupon issue partly refinance debt redemption attractive market environment maturity schedule group bond note outstanding december show table include instrument issue prior genentech transaction bond note nominal amount december contractual maturity dollar euro pound sterling swiss franc total total musd meur mgbp mchf musd mchf total total translate december exchange rate follow group exercise early option december bond redeem march year ahead contractual maturity proceed bond note billion euro swap dollar financial statement economic characteristic equivalent dollardenominate bond note proceed bond note million pound sterling swap dollar financial statement economic characteristic equivalent dollardenominate bond note group plan meet debt obligation exist liquid fund cash generate business operation year free cash flow billion swiss franc include cash generate operation payment interest tax dividend shortterm financing requirement group commercial paper programme united states issue billion dollar unsecured commercial paper note commit credit line billion euro available backstop line commercial paper note total billion dollar outstanding december longerterm financing group maintain strong longterm investmentgrade credit rating moodys standard poor facilitate efficient access international capital market credit rating roche group december shortterm longterm outlook moodys stable standard poor stable describe commentary net debt position group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar time collateral agreement enter derivative counterpartie mitigate counterparty risk roche finance report roche group financial reviewfinancial risk december group net debt position billion swiss franc december billion swiss franc financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security mchf total mchf total cash cash equivalent money market instrument bond debenture investment share total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group billion swiss franc cash fix income marketable security remain strong invest aaaa range note previously group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position december group trade receivables billion swiss franc begin increase financial difficulty certain southern european country notably spain italy portugal greece group lead supplier country trade receivable billion swiss franc public customer country group use different measure improve collection country include intense communication customer negotiation payment plan charge interest late payment legal action group apply new commercial arrangement public hospital greece portugal liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year despite total debt billion swiss franc december roche enjoy strong longterm investmentgrade credit rating moodys standard poor time roche rate high available shortterm rating agency event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market group commit credit line financial institution total billion swiss franc billion swiss franc serve backstop line commercial paper programme december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price var datum table indicate economic loss level period month probability exceed actual future economic gain loss associate treasury activity differ materially var analysis perform inherent limitation associate predict timing change interest rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include credit risk component roche group financial review roche finance report market risk financial instrument december december mchf mchf var interest rate component var foreign exchange component var price component diversification var total interest rate var decrease reflect age debt repayment debt issue debt hold amortise cost interest rate var sole metric economic fair value change impact carry value profit loss group foreign exchange var remain stable price risk arise mainly movement price equity security remain largely stable december group hold equity security market value billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration information financial risk management financial risk var methodology include note consolidated financial statement roche finance report roche group financial reviewinternational financial reporting standard roche group international financial reporting standard ifrs report consolidated result group implement minor amendment exist standard interpretation material impact group overall result financial position new standard issue describe note consolidated financial statement implement latest note base analysis date group anticipate material impact group overall result financial position matter revise version ias employee benefit include follow change exist standard liminating option defer recognition actuarial gain loss define benefit postemployment plan know corridor method group currently apply option use option recognise gain loss comprehensive income option currently apply group henceforth requirement revise standard change impact group financial statement current method include expect income plan asset estimate asset return replace discount rate discount define benefit obligation group estimate method apply consolidated financial statement net financial income approximately million swiss franc lower publish operating profit materially affect roche group financial review roche finance report roche group consolidated financial statement reference number indicate corresponding note consolidated financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statementsroche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche group roche group consolidate financial statement roche finance report roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total roche finance report roche group roche group consolidated financial statementsroche group consolidated balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset associate financial longterm asset longterm asset defer income tax asset postemployment benefit asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer income tax liability postemployment benefit liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity roche group roche group consolidate financial statement roche finance report roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease work capital payment define benefit postemployment plan utilisation provision disposal product operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination divestment subsidiary interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement equity contribution noncontrolle interest interest pay dividend pay equitysettle equity compensation plan net transaction equity instrument finance cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche finance report roche group roche group consolidated financial statementsroche group consolidate statement change equity millions chf non share retain fair value hedge translation control total capital earning reserve reserve reserve total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan total comprehensive income dividend equity compensation plan net transaction equity instrument change noncontrolle interest december year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan total comprehensive income dividend equity compensation plan net transaction equity instrument change noncontrolle interest equity contribution noncontrolle interest december roche group roche group consolidate financial statement roche finance report note roche group consolidate financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement annual financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve issue board director january subject approval annual general meeting shareholder march preparation annual financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change consolidation policy financial statement annual financial statement roche holding ltd company register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enterprise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right currently exercisable potential voting right company share capital special purpose entity consolidate substance relationship special purpose entity control group company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control investment associate account equity method company group exercise power exercise significant influence control normally evidence group own voting right currently exercisable potential voting right company balance transaction associate result unrealised income eliminate extent group interest associate interest joint venture report linebyline proportionate consolidation method roche finance report roche group note roche group consolidated financial statementssegment reporting purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include cec global group function communication human resource finance include treasury taxis pension fund management legal safety environmental service subdivisional information roche pharmaceutical chugai operate segment pharmaceutical division present transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation group company use local currency functional currency certain group company use currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive income disposal foreign entity identify cumulative currency translation difference comprehensive income relate foreign entity recognise income gain loss divestment revenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid united states similar rebate country deduct sale record accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient revenue record earn service perform necessary single transaction split separately identifiable component reflect substance transaction conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction roche group note roche group consolidate financial statement roche finance report cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research cost cost incur purpose gain new scientific technical knowledge understanding cost expense incur internal development cost cost incur application research finding knowledge plan develop new product commercial production cost qualify capitalisation intangible asset follow criterion demonstrate technical feasibility complete development project successfully available use sale intention complete development project ability use sell result development project development project generate economic benefit normally evidence existence size market result project product result project availability adequate technical financial resource complete development project ability measure development expenditure reliably qualify capitalisation intangible asset development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation meet prior obtain marketing approval regulatory authority major market internal development cost meet criterion expense incur postmarkete study regulatory approval phase cost pharmaceutical business expense incur generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason safety surveillance design detect rare longterm adverse effect large patient population long time period possible early stage development cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure addition internal research development activity group party inlicense similar arrangement alliance partner group acquire inprocess research development asset business combination purchase specific asset inprocess research development resource acquire inlicense arrangement business combination separate purchase capitalise intangible asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy review impairment set impairment property plant equipment intangible asset policy subsequent internal research development cost incur postacquisition treat way internal research development cost available use intangible asset amortise straightline basis period expect benefit review impairment reporting date research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset roche finance report roche group note roche group consolidated financial statementslicense milestone upfront receipt royalty income recognise accrual basis accordance substance respective licensing agreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive upfront milestone similar payment party relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned liability longterm employee benefit discount account time value money material pension postemployment benefit employee cover define benefit define contribution postemployment plan sponsor group company group contribution define contribution plan charge appropriate income statement head operating result year relate accounting reporting define benefit plan base recent actuarial valuation define benefit obligation service cost calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return plan asset discount rate base market yield highquality corporate bond government bond countrie deep market corporate bond past service cost allocate average period benefit vested current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss consist difference assumption actual experience effect change actuarial assumption record directly comprehensive income pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly comprehensive income equity compensation plan certain employee group participate equity compensation plan include separate plan chugai fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equity settle plan increase equity record expense subsequent cash flow exercise vested award record change equity cashsettle plan liability record measure fair value report date movement fair value record appropriate income statement head operating result subsequent cash flow exercise vested award record reduction liability roche group note roche group consolidate financial statement roche finance report property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee lease property plant equipment group substantially risk reward ownership classified finance lease finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt asset acquire finance lease depreciate accordance group policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method lease substantially risk reward ownership transfer group classify operating lease payment operating lease charge income straightline basis period lease group lessor primarily occur diagnostic division asset subject finance lease initially report receivables equal net investment lease asset subject operating lease report property plant equipment lease income finance lease subsequently recognise earn income term lease base effective interest rate method lease income operating lease recognise lease term straightline basis business combination goodwill business combination account acquisition method accounting consideration transfer business combination measure fair value date acquisition consideration include cash pay plus fair value date exchange asset give liability incur assume equity instrument issue group fair value consideration transfer include contingent consideration arrangement fair value directly attributable acquisitionrelated cost expense current period report general administration expense date acquisition group recognise identifiable asset acquire liability assume noncontrolle interest acquire business identifiable asset acquire liability assume initially recognise fair value group acquire ownership acquire business noncontrolle interest record proportion fair value acquire net asset attributable noncontrolle interest roche finance report roche group note roche group consolidated financial statementsgoodwill excess fair value consideration transfer noncontrolle interest acquire business acquisition date fair value previous equity interest acquire business fair value group share identifiable net asset acquire initial accounting business combination incomplete end reporting period provisional amount measurement period provisional amount retrospectively adjust additional asset liability recognise reflect new information obtain fact circumstance exist acquisition date affect measurement amount recognise date know measurement period exceed month date acquisition goodwill amortise tested impairment annually occurrence indication impairment goodwill arise investment associate surplus cost investment group share fair value net identifiable asset goodwill record investment associate change ownership interest subsidiary account equity transaction occur control obtain result loss control intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination fair value allocate acquisition account intangible asset amortise useful life straightline basis beginning point available use estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost sell value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm interest rate impairment loss arise useful life asset question review necessary future depreciationamortisation charge accelerate impairment financial asset discuss financial asset policy impairment goodwill goodwill assess possible impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit describe note recoverable cashgenerate unit high fair value cost sell value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss methodology impairment testing describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense roche group note roche group consolidate financial statement roche finance report account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record difference carry value estimate recoverable objective evidence group able collect amount estimate base specific indicator age customer balance specific credit circumstance group historical experience take account economic condition expense doubtful trade receivables recognise consolidated income statement marketing distribution expense trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience longterm account receivable discount account time value money material cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition statement cash flow provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise take account foreign currency effect arise translation functional currency swiss franc time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available fair value hierarchy valuation technique incorporate observable market datum market condition factor likely affect fair value financial instrument valuation technique typically derivative financial instrument fair value financial asset liability report date materially different report carry value specifically mention note annual financial statement information fair value hierarchy include note risk management financial asset financial asset principally investment include marketable security classify fairvaluethroughprofit orloss availableforsale heldtomaturity loan receivables fairvaluethroughprofitorloss financial asset classify heldfortrade designate initial recognition heldfortrade financial asset acquire principally generate profit shortterm fluctuation price financial asset designate fairvaluethrough profitorloss result relevant information eliminate measurement recognition inconsistency heldtomaturity financial asset security fix maturity group intent ability hold maturity loan receivables financial asset create group acquire issuer primary market nonderivative financial asset fix determinable payment quote active market financial asset consider availableforsale roche finance report roche group note roche group consolidate financial statementsall financial asset initially record fair value include transaction cost asset fairvaluethrough profitorloss exclude transaction cost purchase sale recognise settlement date fairvalue throughprofitorloss financial asset subsequently carry fair value change fair value record financial income period arise heldtomaturity financial asset subsequently carry amortise cost effective interest rate method availableforsale financial asset subsequently carry fair value unrealise change fair value record comprehensive income interest calculate effective interest rate method foreign exchange component availableforsale financial asset sell impair dispose cumulative gain loss previously recognise comprehensive income include financial income current period loan receivables subsequently carry amortise cost effective interest rate method financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity security market value original cost net previous impairment consider impair availableforsale equity security market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment sustained sixmonth period consider objective evidence impairment movement fair value record comprehensive income objective evidence impairment asset sell dispose financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry comprehensive income difference original cost net previous impairment fair value impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly comprehensive income financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer interest transfer financial asset create retain group recognise separate asset liability derivative derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedging instrument discuss hedge accounting policy change fair value record financial income period arise embed derivative recognise separately closely related host contract host contract carry amortise cost hedge accounting purpose hedge accounting hedging relationship type fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge net investment foreign operation hedge foreign currency exposure net investment foreign operation roche group note roche group consolidate financial statement roche finance report qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence cash flow hedge hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income qualify cash flow hedge hedge instrument record fair value portion change fair value effective hedge include comprehensive income remain ineffective portion report financial income hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial asset liability cumulative change fair value hedge instrument record comprehensive income include initial carrying value asset liability date recognition qualify cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include comprehensive income remain ineffective portion record financial income hedge instrument derivative comprehensive income case entity dispose cumulative change fair value hedge instrument record comprehensive income reclassify income debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method group derecognise financial liability contractual obligation discharge cancel expired taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future deferred income tax asset liability recognise temporary difference tax basis asset liability carry value financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy taxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction group operate roche finance report roche group note roche group consolidate financial statementsown equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet potential obligation employee arise respect certain group equity compensation plan management judgement apply accounting policy application group accounting policy require management judgement apart involve estimate significant effect amount recognise annual financial statement management judgement particularly require assess substance transaction complicate structure legal form include limited follow area revenue recognition nature group business sale transaction simple structure sale agreement consist multiple component occur different time group party outlicensing agreement involve upfront milestone payment occur year agreement involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement consolidation subsidiary associate group periodically undertake transaction involve obtain right control significantly influence operation company transaction include acquisition equity company purchase certain asset assumption certain liability contingent liability company enter alliance agreement company include transaction involve special purpose entity similar vehicle case management make assessment group right control significantly influence company operation base assessment company consolidated subsidiary associate company make assessment management consider underlie economic substance transaction contractual term business combination group acquire control business identifiable asset acquire liability assume noncontrolle interest acquire business shall recognise separately goodwill process involve management make assessment fair value item management judgement particularly involve recognition measurement follow item intellectual property include patent licence trademark similar right currently market product right scientific knowledge associate project currently research development phase contingency legal environmental matter contingent consideration arrangement recoverability accumulate tax loss previously incur acquire company case management make assessment base underlying economic substance item concern contractual term order fairly present item lease group party leasing arrangement lessee lessor treatment leasing transaction financial statement mainly determine lease consider operate lease finance lease make assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment roche group note roche group consolidate financial statement roche finance report key assumption source estimation uncertainty preparation annual financial statement conformity ifrs require management estimate assumption affect application policy report amount asset liability income expense relate disclosure estimate underlying assumption base historical experience factor believe reasonable circumstance result form basis make judgement carry value asset liability readily apparent source actual result differ estimate estimate underlying assumption review ongoing basis change accounting estimate necessary change circumstance estimate base result new information experience change recognise period estimate revise key assumption future key source estimation uncertainty significant risk cause material adjustment carry value asset liability month describe revenue recognition circumstance level sale return revenue reliably measure case sale recognise right return expire generally prescription product patient order estimate management use publicly available information prescription information provide wholesaler intermediary sale allowance group provision accrual expect sale return chargeback rebate include medicaid united states similar rebate country december total million swiss franc estimate base analyse exist contractual legislativelymandate obligation historical trend group experience management believe total provision accrual item adequate base currently available information deduction base management estimate subject change well information available change arise impact provision accrual recognise balance sheet future period consequently level sale recognise income statement future period allowance doubtful account receivable group provision doubtful receivables december total million swiss franc note estimate base analyse age customer balance specific credit circumstance historical trend group experience take account economic condition management believe total provision accrual item adequate base currently available information provision base management estimate subject change well information available change arise impact provision recognise balance sheet future period consequently market distribution expense recognise income statement future period property plant equipment intangible asset include goodwill group property plant equipment carry value million swiss franc disclose note goodwill carry value million swiss franc note intangible asset carry value million swiss franc note asset review annually impairment describe assess impairment exist estimate future cash flow expect result use asset eventual disposal actual outcome vary significantly estimate discount future cash flow factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment change discount rate lead impairment roche finance report roche group note roche group consolidate financial statementspension postemployment benefit group employee participate postemployment define benefit plan calculation recognise asset liability plan base statistical actuarial calculation particular present value define benefit obligation impact assumption discount rate arrive present value future pension liability assumption future increase salary benefit furthermore group independent actuary use statistically base assumption cover area future withdrawal participant plan estimate life expectancy december present value group define benefit obligation million swiss franc fund plan million swiss franc unfunded plan note actuarial assumption differ materially actual result change market economic condition high low withdrawal rate long short life span participant change factor assess difference impact asset liability recognise balance sheet future period legal provision group company party legal matter include claim arise trade significant matter describe note legal provision december total million swiss franc management believe total provision legal matter adequate base currently available information legal matter involve highly complex issue subject substantial uncertainty probability loss sustained estimate loss difficult ascertain give inherent difficulty estimate liability area guarantee additional cost incur amount accrue additional claim cover exist provision insurance assurance increase scope matter future lawsuit claim proceeding investigation material change arise impact provision recognise balance sheet future period number legal matter possible reasonable estimate expect financial effect result ultimate resolution matter case roche disclose information respect nature fact legal matter disclosure legal matter provide disclose contingent liability seriously prejudice position matter environmental provision group provision environmental remediation cost december total million swiss franc disclose note material component environmental provision consist cost fully clean refurbish contaminate site include landfill treat contain contamination certain site future remediation expense affect number uncertainty include limited detection previously unknown contaminate site method extent remediation percentage problematic material attributable group remediation site relative attributable party financial capability potentially responsible party management believe total provision environmental matter adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amount accrue effect resolution environmental matter result operation predict uncertainty concern time future expenditure change arise impact provision recognise balance sheet future period income taxis december net liability current income taxis million swiss franc net asset defer income taxis million swiss franc disclose note significant estimate require determine current defer asset liability income taxis estimate base interpretation exist tax law regulation management believe estimate reasonable recognise liability income taxrelate uncertainty adequate internal external factor favourable unfavourable effect income tax asset liability factor include limited change tax law regulation andor rate change interpretation exist tax law regulation future level research development spending change overall level pretax earning change arise impact asset liability recognise balance sheet future period roche group note roche group consolidate financial statement roche finance report change accounting policy change accounting policy arise application new revise standard interpretation apply retrospectively transitional requirement particular standard interpretation specify change apply prospectively retrospective application require result comparative period opening balance period restate new accounting policy apply prospective application require new accounting policy apply result current period comparative period restate comparative reclassify extend previously report result account presentational change require application new revise standard interpretation change ifrs implement group implement minor amendment exist standard interpretation material impact group overall result financial position new revise standard follow new standard issue international accounting standard board iasb implement january ifrs consolidated financial statement ifrs joint arrangement ifrs disclosure interest entity ifrs fair value measurement ia revise employee benefit group expect adoption standard list material impact group overall result financial position ias revise employee benefit revise version ias adopt january apply retrospectively matter revise version ias employee benefit include follow change exist standard eliminate option defer recognition actuarial gain loss define benefit postemployment plan know corridor method group currently apply option use option recognise gain loss directly comprehensive income option currently apply group henceforth requirement revise standard change impact group financial statement current method include expect income plan asset estimate asset return replace discount rate discount define benefit obligation group estimate method apply annual financial statement net financial income approximately million swiss franc lower publish operating profit materially affect roche finance report roche group note roche group consolidate financial statement operating segment information divisional information millions chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset impairment net assetsheldforsale equity compensation plan expense roche group note roche group consolidate financial statement roche finance report pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result subdivisional profit elimination profit division operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset impairment net assetsheldforsale equity compensation plan expense net operating asset millions chf asset liability net asset pharmaceutical diagnostic corporate total operating nonoperating group nonoperate asset liability consist primarily balance relate treasury pension taxation matter roche finance report roche group note roche group consolidated financial statementsnet operating asset pharmaceutical subdivisional information million chf asset liability net asset roche pharmaceutical chugai elimination division pharmaceutical division information geographical area millions chf revenue external customer noncurrent asset royalty operate property plant goodwill sale income equipment intangible asset switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group note roche group consolidate financial statement roche finance report supplementary unaudited information sale therapeutic area pharmaceutical division business area diagnostic division give financial review sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue european union information base members december major customer national wholesale distributor amerisourcebergen corp mckesson corp represent approximately billion swiss franc group revenues amerisourcebergen corp billion swiss francs mckesson corp billion swiss franc approximately revenue pharmaceutical operating segment residual diagnostic segment group report substantial revenue national wholesale distributor cardinal health inc total customer represent approximately quarter group revenue chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai fully consolidated subsidiary group december group interest chugai common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement conformity accounting principle generally accept japan jgaap file quarterly basis tokyo stock exchange certain consolidation entry difference requirement international financial reporting standard ifrs jgaap difference chugais standalone result jgaap basis result chugai consolidated roche group accordance ifrs roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche roche finance report roche group note roche group consolidated financial statementsunder rest world umbrella right agreement sign roche right refusal development marketing chugais development compound market outside japan exclude south korea chugai decide require partner activity agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area smallmolecule synthetic drug research biotechnologybase drug discovery dividend dividend distribute party hold chugai share total million swiss franc million swiss franc record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item east japan earthquake march severe earthquake tsunami strike pacific coast tohoku japan consequence chugais operation japan limited impact disaster carefully review operation manufacturing process supply chain damage chugais utsunomiya manufacturing plant result operation temporarily halt production product plant fully resume end august cost record damage cause earthquake mainly relate utsunomiya plant consist impairment restoration cost building partially damage facility writeoff intermediate finish product cost shutdown net amount receive insurance cost record show chugais contract manufacturer affect earthquake result product shipment control last end october chugais promotional activity japan affect event cancel employee resource divert ensure continued product supply information flow customer factor certain negative impact chugais sale second half global issue east japan earthquake cost millions chf cost sale marketing distribution general administration total matter detail chugais equity compensation plan give note roche group note roche group consolidate financial statement roche finance report financial income financing cost financial income million chf year end december gain sale equity security loss sale equity security dividend income gain loss equity security derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security gain loss debt security derivative net writedown impairment longterm loan net interest income income debt security expect return plan asset define benefit plan foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total financial income financing cost million chf year end december interest expense amortisation debt discount gain loss debt derivative net gain loss redemption repurchase bond note net time cost provision interest cost define benefit plan total financing cost net financial income million chf year end december financial income financing cost net financial income financial result treasury management financial result pension management net financial income roche finance report roche group note roche group consolidate financial statement income taxis income tax expense millions chf current income taxis adjustment recognise current tax prior period defer income taxis total income expense group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate group average expect tax rate increase percentage point main driver increase growth proportion group profit generate japan relatively high local tax rate average group rate significant local tax rate change main operating area group compare group effective tax rate increase percentage point percentage point increase average expect tax rate main driver increase nondeductible goodwill impairment group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development manufacturing tax credit state tax impact ther difference group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity million swiss franc million swiss franc income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately million swiss franc million swiss franc record roche group note roche group consolidate financial statement roche finance report tax effect comprehensive income millions chf pretax tax aftertax pretax tax aftertax benefit benefit availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income income tax asset liability millions chf current income taxis sset iabilitie net current income tax asset liability defer income taxis sset iabilitie net defer income tax asset liability movement amount record balance sheet current income taxis show table current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay charge credit income statement current income taxis adjustment recognise current tax prior period charge credit equity equity compensation plan transaction shareholder currency translation effect net current income tax asset liability december roche finance report roche group note roche group consolidate financial statementsdeferred income tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable mchf tax rate mchf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer income tax liability establish withholding tax taxis payable unremitted earning foreign subsidiary amount currently regard permanently reinveste total foreign unremitte earning group billion swiss franc december billion swiss franc movement amount record balance sheet defer income taxis show table defer income taxis movement recognise net asset liability millions chf property post plant intangible employment temporary equipment asset benefit difference total year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect december year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect december defer income tax asset temporary difference mainly relate accrue liability provision unrealise profit inventory roche group note roche group consolidate financial statement roche finance report business combination acquisition verum effective january group acquire control interest privately own company verum diagnostica gmbh verum base munich germany verum specialised coagulation diagnostic focus platelet function test rapidly grow field coagulation market verum report diagnostic operating segment acquisition verum allow group gain market share coagulation segment strengthen lead position clinical diagnostic market purchase consideration million euro million euro pay cash million euro arise contingent consideration arrangement contingent payment arrangement base achievement performancerelate milestone range outcome undiscounte zero million euro liability million swiss franc recognise acquisition date december base management well estimate probability adjust expect cash outflow arrangement purchase consideration million swiss franc allocate show table acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition intangible asset product intangible use inventory defer income taxis net asset liability net identifiable asset liability goodwill purchase consideration impact verum acquisition diagnostic division group report result material acquisition net cash outflow millions chf cash cash net cash consideration pay acquire company outflow acquisition contingent consideration pay prior year acquisition total acquisition pvt effective april group acquire control interest privately own company pvt probenverteiltechnik gmbh base waiblingen germany pvt lab system llc base atlanta georgia united states jointly pvt pvt global market leader provide customise automation workflow solution vitro diagnostic testing large commercial hospital laboratory pvt report diagnostic operating segment acquisition complement strengthen group portfolio clinical diagnostic market purchase consideration pvt probenverteiltechnik gmbh million euro million euro pay cash million euro arise contingent consideration arrangement purchase consideration pvt lab system llc million dollar pay cash contingent payment arrangement base achievement performancerelate milestone arise end range outcome undiscounte million euro liability million swiss franc recognise acquisition date base management good estimate probabilityadjuste expect cash outflow arrangement december recognise arrangement million swiss franc base recent management estimate reflect closing balance sheet foreign exchange rate roche finance report roche group note roche group consolidate financial statementsmtm laboratory effective august group acquire control interest privately own mtm laboratories mtm laboratory base heidelberg germany mtm laboratory develop vitro diagnostic detection diagnosis cancer focus cervical cancer early detection mtm laboratory report diagnostic operating segment acquisition complement group portfolio offer cervical cancer testing roche tissue diagnostic business total purchase consideration million euro million euro pay cash million euro arise contingent consideration arrangement contingent payment arrangement base achievement milestone arise range outcome undiscounte zero million euro liability million swiss franc recognise acquisition date base management good estimate probabilityadjuste expect cash outflow arrangement december recognise arrangement million swiss franc base recent management estimate reflect closing balance sheet foreign exchange rate anadys pharmaceutical effective november group acquire control interest anadys pharmaceuticals inc anadys publicly own company base san diego california prior acquisition anadys list nasdaq symbol ands anadys develop oral small molecule therapeutic potential treatment hepatitis virus hcv infection report roche pharmaceutical operating segment acquisition augment group hcv portfolio total purchase consideration million dollar pay cash combine purchase consideration million swiss franc consist million swiss franc cash million swiss franc contingent consideration arrangement allocate show table acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use arkete intangible inventory defer income taxis cash net asset liability net identifiable asset liability goodwill purchase consideration goodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivables fair value million swiss franc directly attributable transaction cost million swiss franc incur acquisition report general administration expense current period operating result roche pharmaceutical million swiss franc diagnostic operating segment million swiss franc roche group note roche group consolidate financial statement roche finance report acquisition net cash outflow millions chf cash cash net cash consideration pay acquire company outflow acquisition contingent consideration pay prior year acquisition total contingent consideration arrangement group party certain contingent consideration arrangement arise previous business combination arrangement provision arrangement record provision note set table provision contingent consideration arrangement millions chf january additional provision create unused amount reverse utilise year unwind discount business combination erum laboratory currency translation effect december expect outflow resource year year year year total roche finance report roche group note roche group consolidate financial statement global restructuring plan group initiate major global restructuring plan cost incur plan summarise table detail main element plan disclose follow text global restructuring plan cost incur millions chf pharma pharma diagnostic informatic plan total global restructuring cost mployeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost include closure nutley site associate infrastructure environmental remediation cost include restructure apply science diabetes care business area include operational excellence pharmaceutical diagnostic dalcetrapib pharmaceutical pharmaceutical division research development reorganisation june group announce streamline research development activity pharmaceutical division plan site nutley new jersey closed end reduction workforce approximately people research development activity currently undertake nutley consolidated exist site switzerland germany plan translational clinical research center alexandria centre life science manhattan result saving global site consolidation relate infrastructure cost bundle support function shift portfolio allow reallocation resource grow number clinical programme group continue research development activity united states genentech organisation base south san francisco affect reorganisation research development activity diagnostic division chugai affect cost million swiss franc incur base late estimate cost reorganisation million swiss franc provision severance payment employeerelate cost net estimate curtailment gain charge million swiss franc record impairment property plant equipment nutley site addition environmental remediation cost million swiss franc record base initial estimate additional remediation activity need nutley site sell impairment charge intangible asset million swiss franc record result portfolio prioritisation decision link reorganisation note roche group note roche group consolidate financial statement roche finance report diagnostic division apply science diabetes care restructuring initiative announce applied science diabete care business include streamline product portfolio consolidate research development activity increase efficiency marketing distribution operation total cost million swiss franc incur relate employee termination site closure cost addition goodwill impairment charge million swiss franc incur write goodwill nimblegen acquisition result decision exit microarray business reorganisation apply science business area note million swiss franc impairment intangible asset business area note pharmaceutical division global informatic reorganisation half pharmaceutical division announce reorganisation global informatic function division cost million swiss franc incur mainly consist severance payment employee relate cost global restructuring plan november group announce operational excellence global restructuring plan restructuring activity substantially complete end incur total cost billion swiss franc billion swiss franc incur billion swiss franc incur cost million swiss franc incur previously announce operational excellence programme mainly employeerelate cost sale force restructure initiative pharmaceutical division employee relate site closure cost diagnostic division respect site burgdorf switzerland graz austria cost million swiss franc incur mainly employeerelate cost restructure initiative reorganisation cost pharmaceutical division impairment manufacturing site boulder colorado sell august loss divestment research development site madison wisconsin research site kulmbach germany cost partially offset gain disposal site palo alto california sell june second quarter pharmaceutical division initiate detailed review follow announcement result second interim analysis dalcetrapib daloutcome phase iii trial subsequent termination daloutcome trial study dalheart programme restructuring cost million swiss franc incur consist remain trial cost writeoff inventory property plant equipment additionally million swiss franc expense writeoff previously acquire intangible asset note roche finance report roche group note roche group consolidated financial statementsglobal restructuring plan summary cost incur millions chf employeerelate cost ermination cost pension postemployment benefit employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment gain loss disposal property plant equipment site closure cost total site closure cost divestment product business impairment net assetsheldforsale gain loss divestment business total cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost roche group note roche group consolidate financial statement roche finance report global restructuring plan classification cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total cost sale harmaceutical iagnostic marketing distribution harmaceutical iagnostic research development harmaceuticals iagnostic general administration harmaceuticals iagnostic orporate total total operating segment oche pharmaceuticals hugai iagnostics orporate total employee benefit employee remuneration million chf wage salary social security cost define contribution postemployment plan operating expense define benefit postemployment plan equity compensation plan termination cost employee benefit employee remuneration include operating result expect return plan asset define benefit postemployment plan interest cost define benefit postemployment plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit charge employee benefit operating result include relevant expenditure line function expect return plan asset interest cost define benefit plan include financial income financing cost respectively note roche finance report roche group note roche group consolidate financial statement pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group long term financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally united states postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise consequently group postemployment benefit plan classify define benefit plan purpose financial statement define contribution plan define contribution plan typically consist payment employee group fund administer party payment group million swiss franc million swiss franc asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution define benefit plan group major define benefit plan locate switzerland united states germany united kingdom japan plan usually establish trust independent group fund payment group employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss record directly comprehensive income recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly comprehensive income define benefit plan income statement millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total current service cost past service cost gain loss curtailment gain loss settlement total operating expense expect return plan asset interest cost total financial income expense total expense recognise income statement roche group note roche group consolidate financial statement roche finance report fund group define benefit plan oversee corporate level qualified independent actuary carry valuation regular basis major plan annually report date fund plan usually trust independent group finance net assetliability recognise group balance sheet correspond overunder funding plan adjust unrecognised past service cost unfunded plan group meet pension obligation directly financial resource liability define benefit obligation record group balance sheet pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan amount recognise balance sheet postemployment benefit predominantly noncurrent report non current asset liability define benefit plan fund status millions chf fund unfunded fund unfunded plan plan total plan plan total fair value plan asset define benefit obligation funding unrecognise past service cost limit asset recognition reimbursement right net recognise asset liability report balance sheet postemployment benefit asset postemployment benefit liability net recognise asset liability detailed information plan asset define benefit obligation give define benefit plan fair value plan asset reimbursement right millions chf fair value plan asset reimbursement right january expect return plan asset actuarial gain loss currency translation effect employer contribution employee contribution benefit pay fund plan past service cost divestment subsidiary curtailment settlement december roche finance report roche group note roche group consolidated financial statementsdefine benefit plan composition plan asset millions chf share equity instrument bond debenture debt instrument property cash investment roche group nonvoting equity security roche group debt instrument roche group share total investment consist mainly equity fund alternative mortgage commodity insurance policy define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost employee contribution actuarial gain loss currency translation effect benefit pay fund plan benefit pay unfunded plan past service cost divestment subsidiary curtailment settlement december actuarial assumption actuarial assumption unbiase mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate return investment salary benefit level inflation rate cost medical benefit group operate define benefit plan country actuarial assumption vary base local economic social condition demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity roche group note roche group consolidate financial statement roche finance report mortality table major scheme country mortality table germany heubeck table japan mhlw switzerland bvg generational table united kingdom snal rate year female nonpensioner year member future improvement cmi core projection longterm improvement united states project year rate employee turnover disability early retirement base historical behaviour group company financial assumption base market expectation period obligation settle range assumption actuarial valuation significant plan country stable currency interest rate show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate return plan asset expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate calculate discount present value define benefit obligation determine reference market yield highquality corporate bond government bond countrie deep market corporate bond currency term bond consistent obligation discount interest cost include income statement calculate multiply discount rate define benefit obligation define benefit plan sensitivity discount rate millions chf current service cost interest cost define benefit obligation expect return plan asset base market expectation expect return asset fund plan duration relate obligation take account split plan asset equity bond property investment calculation include assumption concern expect dividend interest income realise unrealised gain plan asset taxis administration cost bear plan base longterm market expectation actual performance continually monitor corporate management longterm nature obligation assumption matter return investment necessarily consistent recent historical pattern expect return plan asset include income statement calculate multiplying expect rate return fair value plan asset difference expect return actual return twelvemonth period actuarial gainloss record directly comprehensive income actual return plan asset gain million swiss franc gain million swiss franc roche finance report roche group note roche group consolidated financial statementsexpected rate salary increase calculate define benefit obligation current service cost include income statement base late expectation historical behaviour group company expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance medical cost trend rate calculate define benefit obligation current service cost include income statement postemployment medical plan account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development united states effect percentage point increase decrease medical cost trend rate show define benefit plan sensitivity medical cost trend rate millions chf current service cost interest cost define benefit obligation historical summary fiveyear summary group define benefit plan show table define benefit plan historical information millions chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation experience adjustment actuarial gain loss plan asset experience adjustment change actuarial assumption actuarial gain loss plan liabilitie cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow roche group note roche group consolidate financial statement roche finance report base recent actuarial valuation group expect employer contribution fund plan approximately million swiss franc include estimate million swiss franc additional contribution benefit pay unfunded plan estimate approximately million swiss franc amount record comprehensive income actuarial gain loss recognise statement comprehensive income follow accumulate actuarial gain loss pretax millions chf january actuarial gain loss recognise plan asset liabilitie actuarial gain loss recognise reimbursement right december recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit asset recognition record directly comprehensive income follow limit asset recognition pretax millions chf january increase decrease asset limit recognise year december roche finance report roche group note roche group consolidated financial statement employee stock option equity compensation plan group operate equity compensation plan include separate plan chugai ifrs sharebase payment require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense charge appropriate income statement heading expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense share option plan roche option plan total share option plan equity compensation plan bonus stock award roche connect roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan roche stock appreciation right chugai equity compensation plan total equity compensation plan total operating expense quitysettle ashsettle roche group note roche group consolidate financial statement roche finance report cash inflow outflow equity compensation plan millions chf equitysettle equity compensation plan roche option plan exercise chugai equitycompensation plan exercise roche connect cost total equitysettle equity compensation plan cash outflow transaction equity instrument total cash inflow outflow equitysettle equity compensation plan net transaction equity instrument cashsettle plan include movement net work capital roche stock appreciation right net cash outflow transaction equity instrument mainly arise sale purchase nonvoting equity security genussscheine derivative instrument thereon hold group potential conversion obligation arise group equitysettle equity compensation plan derivative instrument mainly consist option exercisable time maturity note roche longterm group implement new global longterm incentive programme available certain director management employee select discretion group programme consist stock settle stock appreciation right ssar group alternative grant award exist roche option plan follow integration genentech group establish restrict stock unit rsu plan award plan september employee genentech ssar issue accordance roche ssar plan regulation million ssar available issuance tenyear period rsus issue accordance roche restrict stock unit plan regulation million nonvoting equity security available issuance tenyear period remuneration committee determine number nonvoting equity security available plan year plan regulation ssar rsu plan restate amend effective january detail plan give relevant section share option plan roche option plan award plan employee right purchase nonvoting equity security exercise price specify grant date roche option plan regulation restate amend effective january refer roche option plan option nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment roche option plan include provision respect consequence termination employment effect certain corporate transaction authority remuneration committee executive committee interpret administer plan group cover obligation purchase nonvoting equity security derivative thereon note introduction roche longterm number option grant roche option plan significantly reduce eligible employee receive roche stocksettle stock appreciation right instead roche finance report roche group note roche group consolidated financial statementsroche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable number weight average weighted average weight average outstanding year remain exercise price number exercisable exercise price year grant thousands contractual life chf thousand chf total issue roche option plan number option grant underlying equity roche nonvoting equity security currency swiss franc vest period progressively year contractual life year weight average fair value option issue option pricing model binomial input option pricing model share price grant date xercise price xpecte volatility expect dividend yield early exercise factor expect exit rate roche group note roche group consolidate financial statement roche finance report volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour exercise share option weight average share price roche nonvoting equity security year swiss franc equity compensation plan bonus stock award certain member corporate executive committee grant bonus stock award lieu cashsettle bonus financial year issue end april total fair value million swiss franc number award fair value award calculate grant date roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually programme operational october administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million year cost plan million swiss franc million swiss franc report relevant expenditure line function roche stocksettle stock appreciation right introduction roche longterm group offer stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date ssar plan regulation restate amend effective january refer roche ssar plan roche ssar plan million ssar available issuance tenyear period right nontradable equitysettle award sevenyear duration vest phase basis year roche ssar plan include provision respect consequence termination employment effect certain corporate transaction authority remuneration committee executive committee interpret administer plan meaning section title california corporations code section title california code regulation approval annual financial statement constitute approval roche ssar plan describe annual financial statement majority roche hold ltds outstanding security entitle vote group cover obligation purchase nonvoting equity security derivative thereon note roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche finance report roche group note roche group consolidated financial statementsroche ssar term right outstanding december right outstanding right exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total weight average fair value right grant calculate binomial model input model consistent roche option plan award result weight average fair value right swiss franc give total fair value million swiss franc charge vest period year roche restrict stock unit plan group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period rsu plan regulation restate amend effective january refer roche rsu plan roche rsu plan million nonvoting equity security available issuance tenyear period award nontradable represent right receive nonvoting equity security generally vest year period subject performance condition roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant addition roche rsu plan include provision respect consequence termination employment effect certain corporate transaction authority remuneration committee executive committee interpret administer plan provision consistent term applicable california security law meaning section title california corporations code section title california code regulation approval annual financial statement constitute approval roche rsu plan describe annual financial statement majority roche hold ltds outstanding security entitle vote roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december exercisable roche group note roche group consolidate financial statement roche finance report roche performance share plan group offer future nonvoting equity security awards discretion board director cash equivalent certain director key senior manager nontradable equity settle award programme establish beginning currently operate annual threeyear cycle roche performance share plan regulation restate amend effective january refer roche psp plan roche psp plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant addition roche psp plan include provision respect consequence termination employment effect certain corporate transaction authority remuneration committee executive committee interpret administer plan term currently outstanding award set table nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director award result zero nonvoting equity security depend achievement performance target roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million weight average fair value award grant calculate monte carlo simulation input parameter model covariance matrix roche individual company peer group base threeyear history riskfree rate minus valuation take account define rank performance structure determine payout plan chugai stock acquisition right chugai adopt stock acquisition right programme programme allow grant right employee director chugai right issue non tradable equitysettle award tenyear duration vest year right entitle holder purchase chugai share specify exercise price total fair value right issue equivalent million swiss franc million swiss franc calculate binomial model chugai retirement stock acquisition right time chugai issue stock acquisition right lieu retirement gratuity system director abolish right issue thirtyyear duration vest holder retirement director chugai right entitle holder purchase chugai share exercise price japanese yen total fair value right issue equivalent million swiss franc million swiss franc calculate binomial model roche finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment movement carry value asset millions chf building machinery land construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january addition disposal business combination divestment subsidiary transfer reclassification assetsheldforsale depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january addition disposal business combination transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value roche group note roche group consolidate financial statement roche finance report impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence result shorten useful life impairment impairment charge million swiss franc million swiss franc report cost sale million swiss franc market distribution million swiss franc million swiss franc research development million swiss francs general administration income receive insurance company respect impairment property plant equipment million swiss franc borrowing cost capitalise property plant equipment lease arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc carry value lease obligation million swiss franc million swiss franc report debt note finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value future payment minimum lease payment year year year total future finance charge total future minimum lease payment undiscounte operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swiss franc million swiss franc operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment lease arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method roche finance report roche group note roche group consolidated financial statementsfinance lease future minimum lease payment noncancellable lease millions chf present value future gross investment lease minimum lease payment year year year total unearned finance income unguaranteed residual value net investment lease accumulate allowance uncollectible minimum lease payment million swiss franc million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straightline basis december machinery equipment original cost million swiss franc million swiss franc net book value million swiss franc million swiss franc lease party contingent rent recognise income operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment capital commitment group noncancellable capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc roche group note roche group consolidate financial statement roche finance report goodwill goodwill movement carry value asset millions chf january cost accumulate impairment net book value year end december january business combination divestment subsidiary impairment charge currency translation effect december cost accumulate impairment net book value allocate follow cashgenerating unit roche pharmaceutical chugai total pharmaceutical division diabetes care professional diagnostic molecular diagnostic apply science tissue diagnostic strategic goodwill hold divisional level allocate business area total diagnostic division goodwill arise investment associate classify investment associate note goodwill impairment testing pharmaceutical division division subdivision cashgenerate unit test goodwill chugai recoverable base fair value cost sell determined reference publicly quote share price chugai share roche pharmaceutical recoverable impairment testing base value use cash flow projection roche pharmaceutical impairment testing base recent business plan approve management business plan include management late estimate sale volume pricing production operating cost assume significant change organisation roche finance report roche group note roche group consolidated financial statementsthe business plan project year valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model data capital market include government twentyyear bond weight average tax rate calculation correspond pretax discount rate diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division recoverable impairment testing base value use cash flow projection base recent business plan approve management business plan include management late estimate sale volume pricing production operating cost business plan assume significant change organisation apply science restructuring explain business plan project year tissue diagnostic business area project year reflect longterm nature business valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model data capital market include government twentyyear bond weight average tax rate calculation correspond pretax discount rate diagnostic division announce global restructure initiative disclose note plan streamline product portfolio apply science business division exit microarray business microarray business acquire acquisition nimblegen result decision microarray business long consider apply science business area cashgenerating unit assess goodwill impairment give plan exit microarray business goodwill arise nimblegen acquisition consider fully impair charge million swiss franc record remain goodwill million swiss franc apply science business area support value use ongoing business dependent success plan streamline product portfolio goodwill sensitivity analysis management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount rate combine decrease forecast cash flow result sensitivity analysis demonstrate change key assumption cause carry value goodwill exceed recoverable roche group note roche group consolidate financial statement roche finance report intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january business combination addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment oche pharmaceuticals hugai iagnostic total group year end december january business combination addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment oche pharmaceuticals hugai iagnostic total group roche finance report roche group note roche group consolidated financial statementssignificant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use tanox acquisition roche pharmaceutical year corangeboehringer mannheim acquisition diagnostic year ventana acquisition diagnostic year product intangible available use intermune alliance roche pharmaceutical ventana acquisition diagnostic classification amortisation impairment expense millions chf amortisation impairment amortisation impairment cost sale harmaceutical iagnostic marketing distribution iagnostic research development harmaceuticals iagnostic general administration harmaceuticals total internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful live intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase december carry value asset pharmaceutical division million swiss franc approximately represent project potential decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project question result commercialise product intangible asset impairment impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment intangible asset impairment charge total impairment charge million swiss franc million swiss franc roche pharmaceutical operating segment million swiss franc diagnostic operating segment roche group note roche group consolidate financial statement roche finance report pharmaceutical division impairment charge total million swiss franc arise global restructuring initiative disclose note follow recent dalcetrapib trial result impairment charge million swiss franc incur respect previously acquire intangible asset additionally impairment charge million swiss franc record follow portfolio prioritisation decision reorganisation research development pharmaceutical division asset concern amortise fully write impairment charge million swiss franc record follow portfolio prioritisation decision pharmaceutical division relate decision return global right monoclonal antibody antiplgf mab alliance partner asset concern amortise fully write charge impairment charge million swiss franc record follow late clinical datum assessment project acquire marcadia acquisition asset concern amortise write recoverable value million swiss franc follow recent clinical datum impairment charge million swiss franc record respect project collaboration alliance partner asset concern amortise fully write charge addition impairment charge million swiss franc record relate decision stop development compound alliance partner asset concern amortise fully write charge diagnostic division impairment charge million swiss franc record include million swiss franc global restructuring initiative apply science diabete care business note asset concern partly amortise write recoverable value million swiss franc intangible asset impairment charge total impairment charge million swiss franc million swiss franc roche pharmaceutical operating segment million swiss franc diagnostic operating segment pharmaceutical division impairment charge million swiss franc record related decision stop development project acquire business combination outlicense alliance partner asset concern partly amortise write recoverable value million swiss franc charge million swiss franc record result portfolio prioritisation decision project acquire separately business combination asset concern amortise fully write charge diagnostic division impairment charge million swiss franc record mainly respect intangible asset use follow regular updating division business plan technology assessment second half asset concern write recoverable million swiss franc potential commitment alliance collaboration group party inlicense similar arrangement alliance partner arrangement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration agreement group current estimate future thirdparty commitment payment set table figure undiscounted risk adjust meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business roche finance report roche group note roche group consolidated financial statementspotential future thirdparty collaboration payment december millions chf pharmaceutical diagnostic group year year year total associate group investment associate account equity method goodwill arise investment associate classify investment associate investments associate millions chf january share net income currency translation effect december group significant investments associate material transaction group associate additional information associate give note financial longterm asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset longterm employee benefit total longterm asset financial longterm asset hold strategic purpose classify noncurrent availableforsale investment mainly equity investment primarily investment private biotechnology company keep group strategic alliance effort unquoted equity investment classify availableforsale measure cost fair value measure reliably carry value equity investment hold cost million swiss franc million swiss franc million swiss franc loan receivable comprise loan party term year roche group note roche group consolidate financial statement roche finance report inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory expense relate inventory expense cost sale total million swiss franc million swiss franc account receivable account receivable million chf trade account receivable note receivable receivables allowance doubtful account chargeback allowance total account receivable december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc billion swiss franc allowance doubtful account receivable movement recognise liability million chf january additional allowance create unused amount reverse utilise year currency translation effect december expense relate bad debt expense marketing distribution total million swiss franc million swiss franc significant concentration trade receivables counterparty credit risk describe note roche finance report roche group note roche group consolidate financial statement current asset current asset millions chf accrue interest income derivative financial instrument restrict cash receivables total financial current asset prepay expense tax recoverable asset total nonfinancial current asset total current asset derivative financial instrument asset primarily relate hedge nonus dollardenominated bond note issue finance genentech transaction increase compare december mainly strengthen euro compare dollar marketable security marketable security millions chf financial asset fairvaluethroughprofitorloss bond debenture total financial asset fairvaluethroughprofitorloss heldtomaturity financial asset money market instrument time account month total heldtomaturity financial asset availableforsale financial asset hare bond debenture money market instrument time account month ther investment total availableforsale financial asset total marketable security marketable security hold fund management purpose classify current primarily denominate swiss franc dollar euros investment hold strategic purpose classify noncurrent note roche group note roche group consolidate financial statement roche finance report bond debenture carry value contract maturity debt security show bond debenture millions chf contract maturity year year year total bond debenture money market instrument contract mature year december cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent account payable account payable million chf trade account payable taxis payable dividend payable account payable total account payable accrue current liability accrue liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability roche finance report roche group note roche group consolidate financial statement derivative financial instrument group use derivative financial instrument risk management activity discuss note derivative financial instrument carry fair value method determine fair value describe note derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract rosscurrency swap ther interest rate derivative waps ther derivative total derivative financial instrument hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropriate certain risk manage derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income group generally limit use hedge account certain significant transaction consequently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe cash flow hedge group issue bond note finance genentech transaction note bond note denominate euros sterling group enter crosscurrency swap hedge foreign exchange interest rate risk december instrument designate qualify hedge accounting record asset fair value million swiss franc asset million swiss franc ineffective portion group enter foreign exchange forward contract hedge foreign translation exposure euro december instrument designate qualify hedge accounting record liability fair value million swiss franc ineffective portion roche group note roche group consolidate financial statement roche finance report expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total month month month year year year year year year end december cash inflow cash outflow total year end december cash inflow cash outflow total undiscounted cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity expect cash flow qualify cash flow hedge impact profit loss million chf total month month month year year year year year year end december cash inflow cash outflow total year end december cash inflow cash outflow total change hedge reserve equity show note fair value hedge group enter interest rate swap hedge fixedterm debt instrument instrument designate qualified fair value hedge record balance sheet december asset fair value million swiss franc asset million swiss franc loss million swiss franc record interest rate swap gain million swiss franc fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument group equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure group enter forward contract designate qualify fair value hedge december instrument record liability fair value million swiss franc liability million swiss franc loss million swiss franc record forward contract loss million swiss franc result forward contract offset change fair value hedge equity investment group use derivative designate qualify hedge relationship manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forward contract option roche finance report roche group note roche group consolidate financial statement provision contingent liability provision movement recognise liability million chf legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise year unwind discount business combination cquired company ontingent consideration contingent consideration utilisation divestment subsidiary currency translation effect december urrent portion oncurrent portion total provision year end december january additional provision create unused amount reverse utilise year unwind discount business combination cquired company ontingent consideration contingent consideration utilisation currency translation effect december urrent portion oncurrent portion total provision expect outflow resource year year year year total provision roche group note roche group consolidate financial statement roche finance report legal provision legal provision consist number separate legal matter include claim arise trade group company majority cash outflow matter expect occur year dependent development litigation significant provision discount time value money material legal expense total million swiss franc million swiss franc reflect recent development legal matter detail major legal case outstanding disclose environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict estimate timing cash outflow show table significant provision discount time value money material disclose note restructure plan streamline research development activity pharmaceutical division include closure site nutley new jersey expense million swiss franc record base estimate additional remediation activity need nutley site sell expense record increase estimate remediation cost landfill site near grenzach germany manufacturing operation close year ago restructure provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain global basis show table provision discount time value money material matter restructure provision create primarily relate plan streamline research development activity pharmaceutical division mainly relate closure site nutley new jersey employee provision relate certain employee benefit obligation sabbatical leave longservice benefit timing cash outflow reasonably estimate base past performance show table significant provision discount time value money material provision timing cash outflow nature uncertain good estimate show table significant provision discount time value money material provision million chf sale return contingent consideration item total provision roche finance report roche group note roche group consolidate financial statementscontingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note pharmaceutical legal case accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action united states relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder december hlr defend approximately action involve approximately plaintiff bring federal state court united states personal injury allegedly result use accutane action allege ibd result accutane use june hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product united states action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation united states district court middle district florida tampa division july district court grant summary judgment favour hlr federal ibd case proceed august ruling affirm united states court appeal eleventh circuit plaintiff appeal multiple recently file matter remain pende action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county december juries superior court rule favour plaintiff case assess total compensatory damage total million dollar rule favour hlr case case originally rule favour plaintiff superior court hlr process appeal case million dollar case schedule retrial april million dollars posttrial briefing ongoing case million dollar case verdict reverse favour hlr million dollar trial involve plaintiff reach defence verdict case award compensatory damage million dollar case case posttrial briefing august new jersey appellate division reverse verdict favour plaintiff million dollar direct final judgment enter hlr court hold control florida case law hlr entitle judgment prescribing physician testify prescribe accutane face plaintiff propose different warning plaintiff establish respective case new jersey supreme court decline plaintiff request review decision additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive future trial result group continue defend vigorously remain personal injury case claim roche group note roche group consolidate financial statement roche finance report cabilly patent october glaxo group limited smithkline beecham corporation glaxosmithkline llc collectively gsk file patent lawsuit genentech city hope district court southern district florida lawsuit relate patent cabilly patent coowne genentech city hope february gsk dismiss florida lawsuit entirety file related action day district court northern district california subsequently transfer central district california lawsuit gsk seek declaratory judgment patent invalidity unenforceability regard cabilly patent patent noninfringement regard gsk arzerra product half additional lawsuit genentech gsk andor human genome sciences inc hgs involve cabilly patent relate patent cabilly iii patent file district court district delaware central district california lawsuit file delaware subsequently transfer central district california additional lawsuit include claim gsk andor hgs cabilly patent infringe invalid unenforceable genentech violate antitrust unfair competition law law claim genentech gsk arzerra product gsk hgss benlysta product infringe cabilly patent march party agree settlement claim lawsuit relate arzerra product december party agree settlement remain claim lawsuit include related benlysta product matter conclude rituxan arbitration sanofihoechst october genentech biogen idec inc file complaint sanofiaventis deutschland gmbh sanofi sanofiaventis llc sanofiaventis inc northern district california seek declaratory judgment certain genentech product include rituxan infringe sanofis patent declaratory judgment patent invalid october sanofi file suit genentech biogen idec eastern district texas lufkin division claim rituxan genentech product infringe patent sanofi request preliminary permanent injunction compensatory exemplary damage relief subsequently texas california case consolidated northern district california march district court rule matter law genentech biogen idec infringe assert patent claim sanofi file notice appeal court noninfringement rule claim construction order appellate court affirm district court judgment rituxan product infringe claim patent addition october hoechst gmbh file icc international court arbitration paris request arbitration genentech relate terminate agreement hoechst predecessor genentech pertain patent relate patent outside united states hoechst seek payment royalty sale genentech product damage breach contract relief june icc arbitrator issue intermediate decision indicating rituxan cover terminate agreement order genentech produce certain rituxan sale information december october group expect arbitrator use information possibly information determine damage award hoechst december group record royalty expense million swiss franc net assume reimbursement portion group obligation copromotion partner corresponding accrue liability december accrue continue represent management well estimate compensatory damage include interest award hoechst base financial term terminate agreement final decision vary amount provide nature andor extent damage award hoechst differ group estimate genentech successfully challenge arbitrator decision july genentech file declaration appeal court appeal paris initiate legal proceeding challenge arbitrator decision arbitrator subsequently state party june decision decide operative underlie issue liability respect rituxan light statement genentech pursue previously file action challenge arbitrator decision prejudice ability bring challenge future march genentech complete briefing liability owe license agreement arbitrator find liability september arbitrator issue decision indicate genentech liable hoechst certain damage determine november arbitrator hold hearing damage genentech owe hoechst arbitrator issue decision damage december genentech file declaration appeal court appeal paris initiate legal proceeding challenge arbitrator decision roche finance report roche group note roche group consolidated financial statementson genentech file motion district court seek enjoin sanofi affiliate hoechst pursue award icc arbitration undermine contrary court final judgment infringement district court deny motion genentech appeal court appeal federal circuit appeal hearing hold january decision expect later outcome matter determined time average wholesale price litigation hlr roche laboratories inc rli approximately brand generic pharmaceutical company name defendant legal action united states relate pricing pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresented report inaccurate average wholesale price awp wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend awp action file state new jersey discovery currently pende case hlr rli vigorously defend matter outcome matter determined time brand prescription drug litigation hlr brand pharmaceutical company name defendant legal action united states bring retail pharmacy relate discount practice brand prescription drug bnpd bnpd litigations plaintiff allege deny discount certain prescription drug offer mail order manage care entity denial claim violation robinsonpatman act rpa rpa federal law prohibit unlawful price discrimination addition plaintiff allege defendant conspire refusal offer certain discount conspiracy claim defendant previously settle rpa claim remain litigate december hlr rli successfully obtain dismissal bnpd case long defend matter matter conclude university pennsylvania litigation genentech file patent lawsuit university pennsylvania district court northern district california lawsuit relate patent seek declaratory judgment patent noninfringement invalidity regard patent july university counterclaimed genentech infringement patent seek unspecified damage base sale herceptin court issue claim construction order construe certain term claim patent june party enter bind term sheet settle litigation party dismiss case stipulation matter conclude pdl litigation august pdl biopharma pdl file complaint genentech nevada state court seek judicial declaration concern genentech obligation pay royalty certain exus sale herceptin avastin xolair lucentis agreement party september pdl file amend complaint assert additional claim genentech include breach contract breach imply covenant good faith fair dealing pdl assert new claim roche novartis intentional interference contractual relation addition declaratory relief pdl seek monetary damage include compensatory liquidate damage november genentech roche file motion dismiss failure state claim roche file additional motion dismiss lack personal jurisdiction july court deny motion pdl settle claim novartis fact discovery party ongoing expect complete march trial currently schedule october addition litigation pdl conduct royalty audit relate sale avastin herceptin lucentis xolair raptiva year october group receive pdl copy independent auditor final audit report audit report indicate pdls interpretation certain contract term genentech owe pdl additional royalty audit period interpretation genentech owe additional royalty year subsequent audit period group dispute pdls interpretation relevant contract term believe additional royalty owe outcome matter determine time roche group note roche group consolidate financial statement roche finance report gsk litigation september gsk genentech file patent lawsuit case gsk roche holding ltd district court district delaware northern district california respectively lawsuit concern gsk patent nos gsk assert claim genentech roche allege infringement patent certain therapeutic antibody product complaint specifically refer herceptin lawsuit genentech seek judicial declaration noninfringement certain genentech product delaware action november genentech file motion dismiss failure state claim motion transfer case california roche file motion dismiss lack personal jurisdiction party subsequently stipulate roche dismissal genentech remain party march delaware court deny genentech motion transfer case california june party agree dismiss california action prejudice case proceed delaware outcome matter determine time boniva litigation hlr genentech roche affiliate collectively roche name defendant numerous legal action united states canada relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw onj atypical femoral fracture december hlr defend approximately action involve approximately plaintiff bring federal state court united states action bring court queen bench province saskatchewan canada personal injury allegedly result use boniva case early discovery stage litigation individual trial result depend variety factor include unique particular case roche vigorously defend matter outcome matter determine time ema investigation october european medicines agency ema announce start infringement procedure investigate allegation allege breach medicine safety report obligation relation centrally authorise medicine investigation month conclude base datum review submit ema date impact safety profile product find date ema health authority confirm medicine remain authorised change treatment advice patient healthcare professional corrective preventative action result inspection complete newly define process implement routine practice outcome investigation determine time diagnostic legal case marsh supermarket litigation july marsh supermarkets inc marsh file breach contract suit roche diagnostic operation inc rdo lawsuit relate termination sublease agreement building rdo extensive argument bench trial hamilton superior court judge award marsh damage amount million dollar accrue legal provision rdo appeal judgment decision expect half outcome appeal determine time noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability longterm liability consist mainly accrue longterm employee benefit roche finance report roche group note roche group consolidate financial statement debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt gain loss redemption repurchase bond note net amortisation debt discount foreign currency transaction gain loss net currency translation effect december consist bond note ommercial paper amount bank financial institution finance lease obligation ther borrowing total debt report ongterm debt hortterm debt total debt fair value bond note billion swiss franc billion swiss franc billion swiss franc fair value total debt billion swiss franc billion swiss franc billion swiss franc calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period pledge group asset connection debt roche group note roche group consolidate financial statement roche finance report bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollardenominated note float rate month libor note february principal million dollar dollardenominated note fix rate note march principal billion dollar outstanding billion dollars isin usual usaq note march principal billion dollars isin usuam usas note march principal billion dollars isin usuan usau european medium term note programme fix rate note march principal billion euro outstanding billion euro isin note march principal billion pound sterle outstanding billion pound sterling isin note march principal billion euro outstanding billion euro isin note june principal billion euro isin note march principal billion euro isin note august principal million pound sterle outstanding million pound sterling isin swiss franc bond float rate month libor note september principal billion swiss franc swiss franc bond bond march principal billion swiss franc isin bond march principal billion swiss franc isin bond september principal billion swiss franc isin bond september principal billion swiss franc isin genentech senior note senior note july principal billion dollar isin usag senior note july principal million dollar isin usac total roche finance report roche group note roche group consolidated financial statementsbond note maturity million chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond pound sterling note total unamortised discount issuance bond note group raise net proceed approximately billion swiss franc series debt offering describe newly issue debt senior unsecured guarantee roche holding ltd european medium term note march group issue eurodenominate fix rate note term proceed note follow issuance european medium term note effective interest principal net proceed rate eur millions chf millions fix rate eur note total swiss francdenominate bond march group complete offer swiss francdenominate fix rate float rate bond term proceed bond follow issuance swiss francdenominate bond effective interest principal net proceed rate chf millions chf million float rate month libor bond fix rate bond fix rate bond total issuance bond note group issue bond note roche group note roche group consolidate financial statement roche finance report redemption repurchase bond note redemption swiss francdenominate note date march group redeem note principal outstanding million swiss franc original issue plus accrue original issue discount effective interest rate note cash outflow million swiss franc gain loss record redemption partial repurchase eurodenominate note march group complete tender offer nominal million euro fix rate note march total principal outstanding million euro cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc november group complete tender offer nominal million euro fix rate note march total principal outstanding million euro cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc addition group terminate currency swap hedge foreign currency risk eurodenominate note create additional loss million swiss franc reflect change fair value hedge derivative change interest rate total loss repurchase million swiss franc record financing cost note effective interest rate note repurchase partial repurchase eurodenominate note november group complete tender offer nominal million euro fix rate note march total principal outstanding billion euro cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc addition group terminate currency swap hedge foreign currency risk eurodenominate note create additional loss million swiss franc reflect change fair value hedge derivative change interest rate total loss repurchase million swiss franc record financing cost note effective interest rate note repurchase early redemption dollardenominated note december group resolve exercise option redemption entire outstanding dollardenominated fix rate note march group redeem remain outstanding principal billion dollar march equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal treasury rate determine independent investment banker business day precede redemption cash outflow approximately million dollar plus accrue interest expect redemption group revise carrying value note account change amount timing estimate cash flow revise carrying value note december million dollar million swiss franc increase carry value million dollar million swiss franc record financing cost note loss redemption effective interest rate note redemption repurchase bond note redemption dollardenominated note date february group redeem note principal million dollar original issue plus accrue original issue discount effective interest rate note months libor plus cash outflow million swiss franc gain loss record redemption partial early redemption dollardenominated note december group resolve exercise option redemption portion dollardenominate fix rate note march group redeem billion dollar total principal billion dollar note march equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow million swiss franc plus accrued interest december group revise carry value note account change amount timing estimate cash flow increase carry value million swiss franc record financing cost additional loss million swiss franc incur final settlement note effective interest rate note roche finance report roche group note roche group consolidate financial statementspartial repurchase eurodenominate note june group complete tender offer nominal million euro fix rate note march total principal billion euro cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc addition group terminate currency swap hedge foreign currency risk eurodenominate note create additional loss million swiss franc reflect change fair value hedge derivative change interest rate total loss repurchase million swiss franc record financing cost effective interest rate note repurchase partial repurchase swiss francdenominate bond november group complete tender offer nominal million swiss franc fix rate bond march total principal billion swiss franc cash outflow million swiss franc plus accrued interest loss repurchase bond million swiss franc effective interest rate bond repurchase partial repurchase pound sterlingdenominate note december group complete tender offer nominal million pound sterling fix rate note march total principal billion pound sterle cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc effective interest rate note repurchase partial repurchase pound sterlingdenominate note december group complete tender offer nominal million pound sterling fix rate note august total principal million pound sterle cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc effective interest rate note repurchase cash flow issuance redemption repurchase bond note cash inflow issuance bond note millions chf european medium term note programme eurodenominate note swiss francdenominate bond total cash inflow issuance bond note cash outflow redemption repurchase bond note millions chf swiss francdenominate bond european medium term note programme eurodenominate note european medium term note programme pound sterlingdenominate note dollardenominate note total cash outflow redemption repurchase bond note roche group note roche group consolidate financial statement roche finance report collateral arrangement group enter currency swap certain nonus dollar debt instrument issue collateral agreement enter counterpartie currency swap mitigate counterparty risk fair value derivative instrument increase mainly strengthen euro compare dollar total billion swiss franc cash collateral deliver group year billion swiss franc deliver group collateral deliver record increase cash correspond increase accrue liability carry value accrue liability respect agreement december billion swiss franc december accrue liability billion swiss franc commercial paper roche holdings inc commercial paper program march roche holdings inc establish commercial paper program issue billion dollar unsecured commercial paper note guarantee roche holding ltd commit credit line billion euro available backstop line maturity note program exceed day date issuance december unsecured commercial paper note principal million dollar average interest rate outstanding amount date january movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december amount bank financial institution amount denominate currency notably chinese renminbi argentine peso average interest rate amount outstanding million swiss franc december year roche finance report roche group note roche group consolidate financial statement equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment valuation gain loss take equity transfer income statement sale impairment ncome taxis oncontrolle interest cash flow hedge gain loss take equity transfer income statement ncome taxis oncontrolle interest currency translation foreign operation xchange difference accumulate difference transfer income statement divestment oncontrolle interest define benefit postemployment plan actuarial gain loss limit asset recognition ncome taxis oncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity instrument change noncontrolle interest december entire loss transfer income statement million swiss franc report financial income roche group note roche group consolidate financial statement roche finance report change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment valuation gain loss take equity transfer income statement sale impairment ncome taxis oncontrolle interest cash flow hedge gain loss take equity transfer income statement ncome taxis oncontrolle interest currency translation foreign operation xchange difference oncontrolle interest define benefit postemployment plan actuarial gain loss limit asset recognition ncome taxis oncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity instrument change noncontrolle interest december entire gain transfer income statement million swiss franc report financial income group complete purchase noncontrolle interest genentech effective march base revise international accounting standard consolidated separate financial statement ias adopt group transaction account equity transaction consequence carrying consolidate equity group time reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy roche finance report roche group note roche group consolidate financial statementsshare capital december authorise issue share capital roche holding ltd group parent company consist share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool describe note base information supply group novartis ltd basel affiliates participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board director propose dividend business year swiss franc share nonvoting equity security approve result total distribution shareholder million swiss franc subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security million millions nonvoting equity security derivative instrument total equity instrument record equity original purchase cost detail equity instrument hold december show table fair value disclose information purpose equity instrument december supplementary information equivalent number non vote equity security strike price market value millions maturity chf chf billion nonvoting equity security derivative instrument feb sept total roche group note roche group consolidate financial statement roche finance report nonvoting equity security derivative instrument hold group potential conversion obligation arise roche option plan roche stocksettle stock appreciation right roche restrict stock unit plan note mainly consist option exercisable time maturity group hold share reserve fair value reserve fair value reserve represent cumulative net change fair value availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc earning share nonvoting equity security basic earning share nonvoting equity security calculation basic earning share nonvoting equity security number share nonvoting equity security reduce weight average number nonvoting equity security hold group period basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weight average number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security potential dilutive effect arise employee stock option plan exercise outstanding vested employee stock option dilutive effect exercise outstanding vested chugai stock option dilutive effect net income chugai positive diluted earning share nonvoting equity security reflect potential impact dilutive effect earning share figure roche finance report roche group note roche group consolidated financial statementsdilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement hugai noncontrolle interest total net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income net tax total comprehensive income dividend noncontrolle shareholder hugai noncontrolle interest equity compensation plan net transaction equity instrument change noncontrolle interest equity contribution noncontrolle interest december hugai noncontrolle interest total noncontrolle interest roche group note roche group consolidate financial statement roche finance report statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense ssociate inancial income inancing cost ncome taxis operate profit depreciation property plant equipment amortisation intangible asset impairment goodwill impairment intangible asset impairment property plant equipment impairment net assetsheldforsale operating expense define benefit postemployment plan operating expense equitysettle equity compensation plan net income expense provision bad debt expense inventory writedown adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total roche finance report roche group note roche group consolidated financial statementscash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity dividend pay millions chf dividend roche group shareholder dividend noncontrolle shareholder chugai dividend noncontrolle shareholder dividend withholding tax total significant noncash transaction significant noncash transaction risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management specifically describe detail financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai roche group note roche group consolidate financial statement roche finance report carry value fair value financial asset millions chf carry value asset class fvtpla available heldfor heldto loan line item note forsale trading maturity receivables total fair value year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture hare ther investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture hare ther investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total fairvaluethroughprofitorloss roche finance report roche group note roche group consolidated financial statementsthe table analyse financial instrument carry fair value valuation method different level define follow level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial asset liability december millions chf level level level total financial asset recognise fair value marketable security money market instrument time account month bond debenture hare derivative financial instrument availableforsale investment total financial liability recognise fair value derivative financial instrument total fair value hierarchy financial asset liability december millions chf level level level total financial asset recognise fair value marketable security money market instrument time account month bond debenture hare derivative financial instrument availableforsale investment total financial liability recognise fair value derivative financial instrument total availableforsale investment exclude equity security hold cost million swiss franc million swiss franc carry fair value note december level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument unquoted share significant transfer level level vice versa december group financial asset classify level roche group note roche group consolidate financial statement roche finance report credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset trade receivables subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective management trade receivables sustain growth profitability group optimise asset utilisation whilst maintain risk acceptable level note significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie additionally group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold loan receivables december group combine trade account receivable balance national wholesale distributor amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss franc represent group consolidated trade account receivable billion swiss franc represent december group trade receivables billion swiss franc begin increase financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country trade receivable billion euro billion swiss franc public customer country reduction billion euro december mainly collection spain follow montoro plan increase factoring deal italy group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action group apply new commercial arrangement public hospital greece portugal nature geographic location counterpartie trade receivable overdue show table include overdue balance national wholesalers southern europe public customer describe trade receivables overdue nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total roche finance report roche group note roche group consolidated financial statementscash marketable security subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly investment marketable security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity cash shortterm time deposit subject rule limit group exposure individual financial institution fix income marketable security group hold billion swiss franc government security switzerland counterpartie rating well exception argentina million swiss franc december rate rating analysis cash fix income marketable security market value mchf total mchf total aaarange aarange arange bbbrange bbbrange total derivative group sign net collateral agreement isda international swap derivative association master agreement respective counterpartie order mitigate counterparty risk derivative position group enter derivative contract party hedge foreign exchange risk arise bond note issue group affiliate roche holdings inc currencie dollar total billion swiss franc cash collateral deliver group year billion swiss franc deliver group collateral agreement set cash acceptable collateral collateral received deliver december relate derivative activity overdue asset financial asset past impair total billion swiss franc billion swiss franc analysis overdue impair financial asset class millions chf total overdue month month month month year year end december loan receivables year end december loan receivables december significant financial asset term renegotiate liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time group liquidity report senior management monthly basis roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement addition group unused committed credit line financial institution total billion swiss franc billion swiss franc decline undiscounted financial liability show table mainly debt repayment interest pay roche group note roche group consolidate financial statement roche finance report contractual maturity analysis financial liability millions chf total month month month year year year year year year end december total debt trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability year end december total debt trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability total debt table show undiscounted cash flow carry value consolidate balance sheet reflect discount cash flow market risk market risk arise change market price group financial asset financial liability market risk affect group financial result value group equity group use valueatrisk var measure impact market risk financial instrument roche define var limit manage market risk var datum report monthly basis indicate value range give financial instrument fluctuate preset probability result movement market price var statistical measure implicitly assume value change recent past indicative value change future var figure represent actual expect loss possible worstcase loss state period var figure calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate long hold period increase probability high value change lead increase var figure actual future gain loss associate treasury activity differ materially var analysis perform inherent limitation associate predict timing change interest rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include effect change credit spread roche finance report roche group note roche group consolidated financial statementsmarket risk financial instrument millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate var decrease million swiss franc reflect age debt repayment debt issue debt hold amortise cost interest rate var sole metric economic fair value change impact carry value profit loss group foreign exchange var remain stable price risk arise mainly movement price equity security remain largely stable december group hold equity security market value billion swiss franc december billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration foreign exchange risk group operate world expose movement foreign currency affect group financial result value group equity foreign exchange risk arise local currency pay receive transaction denominate foreign currency vary change exchange rate transaction exposure foreign currency denominate financial statement group foreign subsidiary vary consolidation swiss francdenominate group financial statement translation exposure objective group foreign exchange risk management activity preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group monitor transaction exposure daily basis net foreign exchange result correspond var parameter report monthly basis group use forward contract foreign exchange option cross currency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity change interest rate cause variation interest income expense addition affect market value certain financial asset liability hedge instrument primary objective group interest rate management protect net interest result interest rate exposure correspond var parameter report monthly basis group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment equity price risk report var figure monthly basis senior management roche group note roche group consolidate financial statement roche finance report impairment financial asset impairment loan receivables mainly increase expect nonrecoverability trade receivables writedown debt security million swiss franc relate greek government bond receive exchange trade receivables impairment loss asset class millions chf loan receivables availableforsale financial asset hare nvestment ebt security total impairment loss capital group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event group complete purchase noncontrolle interest genentech effective march consideration net tax effect approximately billion swiss franc base revised international accounting standard consolidated separate financial statement ias adopt group transaction account equity transaction consequence carrying consolidate equity group reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy capital monitor basis capitalisation calculate debt plus equity include noncontrolle interest report senior management group regular internal management reporting group capitalisation show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine local management roche finance report roche group note roche group consolidate financial statement relate party control shareholder share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own share represent issue share group consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool andr hoffmann andreas oeri members board director roche holding ltd hoffmann receive remuneration total swiss franc swiss francs oeri receive remuneration total swiss franc swiss franc transaction group individual member shareholder group subsidiary associate list major group subsidiary associate include note transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associate key management personnel total remuneration key management personnel million swiss franc million swiss franc million swiss franc member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee total remuneration board director exclude chairman total million swiss franc million swiss franc million swiss franc chairman board director member corporate executive committee roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition fair value award disclose note new member corporate executive committee diggelmann hippe oday include table calendar year join cec similarly members corporate executive committee retire way year soriot hunziker include calendar year leave cec remuneration chairman board director member corporate executive committee millions chf salary include cashsettle bonus bonus stock award social security cost pension postemployment benefit equity compensation plan retirement awards employee benefit total roche group note roche group consolidate financial statement roche finance report purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include financial statement roche holding ltd basel page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration chairman board director member corporate executive committee ifrs basis table deduct bonus stock award ifrs basis equity compensation plan ifrs basis add bonus stock award swiss legal basis equity compensation plan swiss legal basis total remuneration chairman board director member corporate executive committee swiss legal basis chairman board director member corporate executive committee bonus stock award certain member corporate executive committee grant bonus stock award lieu cashsettle bonus financial year issue end april total fair value million swiss franc million swiss franc number award fair value award calculate grant date roche longterm member corporate executive committee grant stocksettle stock appreciation right ssar roche option plan rop restricted stock unit rsu award ssar rop rsu award ssar rop rsu award roche connect contribution pay group respect chairman board director member corporate executive committee total million swiss franc million swiss franc million swiss franc roche performance share plan member corporate executive committee target award cycle awards cycle award result zero nonvoting equity security depend achievement performance target transaction member corporate executive committee pension total million swiss franc pay group corporate executive committee member million swiss franc million swiss franc postemployment benefit plan transaction group postemployment define benefit plan employee group describe note roche finance report roche group note roche group consolidated financial statement subsidiary associate divestment subsidiary effective group sell wholly own subsidiary roche vitamins inc rvi party addition group complete sale follow whollyowne subsidiary connection operational excellence programme roche colorado corporation boulder colorado roche madison inc madison wisconsin roche kulmbach gmbh kulmbach germany lascona land company inc philippine total consideration receive divestment million swiss franc consist million swiss franc cash marketable security fair value million swiss franc defer cash consideration million swiss franc receive total gain loss divestment show table gain loss divestment subsidiary millions chf consideration net asset dispose property plant equipment oodwill rovision ash net asset accumulate currency translation adjustment total net asset dispose transaction cost provision accrual residual obligation retain roche group gain loss divestment report global restructuring plan roche pharmaceutical operating segment general administration cost corporate operating segment list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich valor share valor genussschein isin share isin genussschein market capitalisation chf japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin market capitalisation jpy roche group note roche group consolidate financial statement roche finance report nonliste company share capital equity interest country company city millions algeria roche algerie spa bab ezzouar dzd argentina productos roche qumica industrial buenos aire ars vanguardia productos farmacuticos vanprofarma buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur roche diagnostic graz gmbh graz eur belgium roche brussels eur roche diagnostic belgium brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico farmacuticos paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd john cad chile roche chile limitada santiago chile clp china roche china holding ltd shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche bogot cop costa rica roche servicios heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostic hvidovre dkk dominican republic producto roche dominicana santo domingo dop ecuador roche ecuador quito usd salvador productos roche salvador san salvador svc estonia roche eesti tallinn eur finland roche diagnostic espoo eur roche espoo eur france institut roche recherche mdecine translationnelle sas boulognebillancourt cedex eur roche diagnostic france sas meylan eur roche sas boulognebillancourt cedex eur ventana medical systems sas illkirch eur georgia roche georgia llc tbilisi gel germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche mtm laboratories heidelberg eur roche pharma grenzachwyhlen eur roche pvt gmbh waiblingen eur swisslab gmbh berlin eur verum diagnostica gmbh munich eur roche finance report roche group note roche group consolidate financial statementsshare capital equity interest country company city millions greece roche hellas athens eur roche diagnostic hellas athens eur guatemala producto roche guatemala guatemala gtq honduras producto roche honduras tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche product india pvt ltd mumbai inr indonesia roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd petach tikva il italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius light malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd kuala lumpur myr syntex pharmaceutical sdn bhd kuala lumpur myr mauritius roche product mauritius limited quatre borne mur mexico producto roche mexico city mxn roche servicios mxico mexico city mxn morocco roche casablanca mad netherlands roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio nigeria roche product limited lagos ngn norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd panama producto roche panam panama city pab producto roche interamericana panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd peru producto roche qumica farmacutica lima pen philippine roche philippines inc taguig city php poland roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostic rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche product proprietary limited illovo zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw roche group note roche group consolidate financial statement roche finance report share capital equity interest country company city millions spain andreu roche madrid eur roche diagnostic barcelona eur roche farma madrid eur syntex roche madrid eur sri lanka roche product colombo private limited colombo lkr sweden roche stockholm sek roche diagnostic scandinavia bromma sek switzerland hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabete care burgdorf chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd steinhausen chf roche finance ltd basel chf roche forum buonas buonas chf roche glycart schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev usd united arab emirate roche diagnostic middle east fzco dubai ae roche middle east fzco dubai ae united kingdom pirame limited welwyn garden city gbp roche diagnostics ltd burgess hill gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation branford usd alios biopharma inc south san francisco usd anadys pharmaceuticals inc south san francisco usd bioveris corporation indianapoli usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd biofire diagnostic inc salt lake city usd igen international inc pleasanton usd marcadia biotech inc nutley usd roche carolina inc florence usd roche diagnostic corporation indianapoli usd roche diagnostic operation inc indianapoli usd roche holdings inc south san francisco usd roche insulin delivery systems inc fisher usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen iceland llc reykjavik usd roche nimblegen inc madison usd roche tcrc inc nutley usd spring bioscience corp pleasanton usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch hamilton uyu venezuela producto roche caracas vef vietnam roche diagnostic vietnam ltd chi minh city usd share capital local currency unit roche finance report roche group note roche group consolidate financial statementsreport roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set page franz humer alan hippe chairman board directors chief financial officer basel january roche group report roche management internal control financial report roche finance report report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement annual general meeting roche holding ltd basel statutory auditor audit accompany consolidated financial statement roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flow statement change equity note page year end december board director responsibility board director responsible preparation fair presentation consolidate financial statement accordance international financial reporting standard ifrs requirement swiss law responsibility include design implement maintain internal control system relevant preparation fair presentation consolidate financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion consolidated financial statement base audit conduct audit accordance swiss law swiss auditing standard international standard auditing standard require plan perform audit obtain reasonable assurance consolidated financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure consolidated financial statement procedure select depend auditor judgement include assessment risk material misstatement consolidated financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation fair presentation consolidate financial statement order design audit procedure appropriate circumstance audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation consolidated financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion consolidate financial statement year end december true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law roche finance report roche group report statutory auditor consolidated financial statementsreport legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ian starkey franois rouiller license audit expert license audit expert auditor charge basel january roche group report statutory auditor consolidated financial statement roche finance report report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examine roche group system internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting responsibility express opinion company internal control financial reporting base examination entity internal control financial reporting process effect entitys board director management personnel design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entitys asset material effect entitys financial statement conduct examination accordance international standard assurance engagement isae standard require plan perform examination obtain reasonable assurance effective internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe examination provide reasonable basis opinion inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject risk internal control inadequate change condition degree compliance policy procedure deteriorate roche finance report roche group report independent auditor internal control financial reportingin opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg ian starkey franois rouiller license audit expert license audit expert auditor charge basel january roche group report independent auditor internal control financial report roche finance report multiyear overview supplementary information multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard dividend propose board director apply retrospectively roche finance report roche group multiyear overview supplementary informationmultiyear overview supplementary information multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard dividend propose board director apply retrospectively roche group multiyear overview supplementary information roche finance report sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche group multiyear overview supplementary informationaddition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group multiyear overview supplementary information roche finance report supplementary core result ep information group basic diluted earning share information give note annual financial statement page group expand presentation core result previously core ep show income statement group operating result division show ifrs core basis allow transparent assessment actual result underlie performance business core result concept internal management business base ifrs result follow adjustment global restructuring plan note exclude amortisation impairment intangible asset note impairment goodwill note exclude acquisition accounting onetime impact alliance arrangement business combination financial review exclude discontinued operation currently exclude legal environmental expense financial review exclude global issue outside healthcare sector group control exclude include directly attributable cost earthquake occur japan march note item material onetime treasury item major debt restructuring settlement pension plan currently exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial review roche finance report roche group multiyear overview supplementary informationcore result reconciliation million chf alliance normali global intangible business legal sation restruc amorti intangible combi environ global ecp tax ifrs ture sation impairment nation mental issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable oche shareholders oncontrolle interest core result reconciliation million chf alliance normali global intangible business legal sation restruc amorti intangible combi environ global ecp tax ifrs ture sation impairment nation mental issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable oche shareholders oncontrolle interest roche group multiyear overview supplementary information roche finance report divisional core result reconciliation million chf alliance global intangible business legal restruc amorti intangible combi environ global ifrs ture sation impairment nation mental issue core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation million chf alliance global intangible business legal restruc amorti intangible combi environ global ifrs ture sation impairment nation mental issue core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary informationcore ep core net income chf million core net income attributable roche shareholder increase noncontrolle interest share core net income assume outstanding chugai stock option exercise net income calculate diluted earning share share information million share nonvoting equity security weight average number share nonvoting equity security issue adjustment assume exercise equity compensation plan dilutive weight average number share nonvoting equity security issue calculate diluted earning share core earning share dilute chf roche group multiyear overview supplementary information roche finance report supplementary operating free cash flow information divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset impairment net assetsheldforsale total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct net cash flow equitysettle equity compensation plan utilisation provision proceed disposal total operating profit cash adjustment ebitda core operate profit depreciation impairment property plant equipment core basis ebitda margin sale roche finance report roche group multiyear overview supplementary informationsupplementary balance sheet information net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision associate current income tax net asset defer income tax net asset postemployment benefit net asset marketable security cash cash equivalent debt net asset net work capital longterm net operating asset ther total net asset net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision associate current income tax net asset defer income tax net asset postemployment benefit net asset marketable security cash cash equivalent debt net asset net work capital longterm net operating asset ther total net asset roche group multiyear overview supplementary information roche finance report oche securities price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july information table restate change ratio adr effective january change ratio adr effective january roche finance report roche group roche securitiesnumber share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number nonvoting equity security genussscheine hold total issue datum share nonvoting equity security chf earning dilute equity attributable roche shareholder dividend stock price shareb open high low yearend stock price nonvoting equity security genussscheinb opening high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange rog bloomberg rog rhhby reuters ros rogvx rhhbypk roche group roche security roche finance report roche holding ltd basel financial statement note financial statement summary significant accounting policy isk management quity board executive remuneration contingent liability board executive shareholding ignificant shareholder appropriation available earning report statutory auditor financial statement financial statement income statement millions chf year end december income income participation interest income loan group company interest investment income guarantee fee income group company income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year roche holding ltd basel financial statement roche finance report balance sheet million chf december december noncurrent asset participation longterm loan group company total noncurrent asset current asset account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company unrealise foreign currency gain liability total current liability total liability total equity liability pro memoria nonvoting equity security nominal value roche finance report roche holding ltd basel financial statementsnotes financial statement summary significant accounting policy basis preparation financial statement financial statement roche holding ltd basel prepare accordance provision swiss law participation major participation company list note roche group annual financial statement valuation method translation foreign currency marketable security report low cost market value asset include participation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer taxis tax charge include corporate income capital taxis equity share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate movement recognise amount millions chf general legal special available share capital reserve free reserve reserve earnings total equity january income ividend december income ividend december income ividend transfer free reserve december roche holding ltd basel note financial statement roche finance report contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december billion swiss franc billion swiss franc describe note roche group annual financial statement page significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company control shareholder december base information supply group shareholder group pool voting right own share represent issue share group consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool december base information supply group share share own novartis ltd basel include affiliate thereof participation risk management detailed disclosure risk management require swiss law include roche group annual financial statement page roche finance report roche holding ltd basel note financial statement board executive remuneration board director member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee remuneration member board director thousands chf gehrig hoffmann baschera bell bulcke burns ljr vink franz frey julius levinson oeri ruttenstorfer voser weder mauro total remuneration board director annual general meeting march frey ruttenstorfer stand reelection annual general meeting march bulcke franz voser elect new member board director remuneration levinson include payment consult work board membership genentech total thousand swiss franc thousand swiss franc chairman board directors franz humer receive remuneration show table remuneration chairman board director thousands chf annual salary include cashsettled bonus bonus stock award pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total roche holding ltd basel note financial statement roche finance report corporate executive committee member corporate executive committee cec roche holding ltd receive remuneration indirect benefit participate certain equity compensation plan show table group ceo severin schwan member corporate executive committee high total remuneration remuneration disclose new member corporate executive committee diggelmann hippe oday include calendar year join cec similarly members corporate executive committee retire way year soriot hunziker include calendar year leave cec remuneration member corporate executive committee thousands chf total cec schwan total cec schwan total cec schwan annual salary include cashsettled bonus bonus stock award pension postemployment benefit equity compensation plan retirement awards employee benefit total remuneration receive social security cost total bonus stock award certain member corporate executive committee grant bonus stock award lieu cashsettle bonus financial year issue end april total fair value employee thousand swiss franc fair value award employee calculate take account period block year year number award fair value award calculate grant date employer contribution social security scheme pension plan group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee equity compensation plan chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition award disclose note roche group annual financial statement fair value roche group annual financial statement represent cost company grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition purpose remuneration disclosure value calculate base fair value employee receive take account preliminary assessment complete performance condition chairman board director member corporate executive committee eligible participate roche connect programme enable employee regular deduction salary purchase nonvoting equity security group contribute programme allow employee purchase nonvoting equity security discount usually member corporate executive committee grant stocksettle stock appreciation right ssar individual award relate show table fair value award employee thousand swiss franc calculate trinomial model american option roche finance report roche holding ltd basel note financial statementsmember corporate executive committee member senior management participate roche performance share plan psp group overlapping threeyear psp target award threeyear cycle define begin cycle award consider form employee remuneration equal annual amount threeyear cycle award result zero nonvoting equity security depend achievement performance target discretion board director individual award relate show table number award calculate follow psp end cycle performance target achieve accordingly participant receive originally target nonvoting equity security psp nonvoting equity security award psp nonvoting equity security award result allocation multiply nonvoting equity security price december swiss franc fair value remuneration receive employee remuneration equity compensation plan thousand chf roche connect ssar awards psp award employer ssar ssar psp psp psp psp total contribution number fair value number number number fair value fair value total cec schwan employee benefit include tax advisory cost incidental benefit transaction member corporate executive committee pension total million swiss franc pay group corporate executive committee member million swiss franc million swiss franc roche holding ltd basel note financial statement roche finance report board executive shareholding board director director andr hoffmann andreas oeri member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table shareholding member board director nonvoting equity security share genussscheine humer gehrig hoffmann baschera bell bulcke burns ljr vink franz julius levinson oeri voser weder mauro total include share hold shareholder group pool voting right equity compensation award roche option plan ssar roche performance share plan hoffmann oeri hold ubs longshort certificate roche share versus roche nonvoting equity security genussscheine rog vink hold roche american depositary receipt adr close relative dame deanne julius hold roche nonvoting equity security genussscheine humer hold rogtpk trackerplus certificate zrcher kantonalbank underlie roche nonvoting equity security genussscheine rog roche finance report roche holding ltd basel notes financial statementscorporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan ayyoubi diggelmann hippe keller oday soriot total equity compensation award roche option plan ssar roche performance share plan close relative schwan hold roche nonvoting equity security genussscheine close relative keller hold roche share roche share december chairman board director burns members corporate executive committee hold roche option plan award rop stocksettle stock appreciation right ssar show table award hold humer current chairman board director burns current member board director issue previous capacity member corporate executive committee term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include business report annual report page rop ssar award hold december year issue total schwan ayyoubi diggelmann hippe keller oday total cec humer burn total strike price chf expiry date mar feb feb feb jan feb feb hippes awards strike price chf expire april diggelmann awards strike price chf expire july roche holding ltd basel note financial statement roche finance report december members corporate executive committee show table hold psp award psp performance cycle term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report page business report annual report award result zero nonvoting equity security depend achievement performance target discretion board director end cycle performance target achieve accordingly participant receive originally target nonvoting equity security total target number award outstanding performance cycle december show table roche performance share plan award hold december psp psp schwan ayyoubi diggelmann hippe keller oday total cec allocation date feb feb december chairman board director burns members corporate executive committee time hold total stocksettle stock appreciation right outstanding total award grant roche performance share plan roche finance report roche holding ltd basel note financial statementsappropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account roche holding ltd basel appropriation available earning roche finance report report statutory auditor financial statement report statutory auditor financial statement annual general meeting roche holding ltd basel statutory auditor audit accompany financial statement roche holding ltd comprise income statement balance sheet note page year end december board director responsibility board director responsible preparation financial statement accordance requirement swiss law company article incorporation responsibility include design implement maintain internal control system relevant preparation financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion financial statement base audit conduct audit accordance swiss law swiss auditing standard standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure financial statement procedure select depend auditor judgement include assessment risk material misstatement financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation financial statement order design audit procedure appropriate circumstance purpose express opinion effectiveness entity internal control system audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion financial statement year end december comply swiss law company article incorporation roche finance report roche holding ltd basel report statutory auditor financial statementsreport legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ian starkey franois rouiller license audit expert license audit expert auditor charge basel january roche holding ltd basel report statutory auditor financial statement roche finance report publish cautionary statement forwardlooke hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooking statement tel forwardlooke statement identi fie word believe expect anticipate project intend fax seek estimate future similar expression discussion thing strategy goal plan medium office intention factor cause actual result differ group communication materially future reflect forwardlooke basel switzerland statement contain annual report tel pricing product initiative competitor legislative fax regulatory development economic condition delay inability obtain regulatory approval bring product market fluctuation currency exchange rate general investor relation financial market condition uncertainty discovery basel switzerland development marketing new product new use tel exist product include limitation negative result fax clinical trial research project unexpected effect pipeline market product increase government website pricing pressure interruption production loss wwwrochecom inability obtain adequate protection intellectual property right litigation loss key executive employee adverse publicity news coverage order publication tel statement earning share growth profit fax forecast interpret mean roche email baselwebmasterrochecom earning earning share subsequent period necessarily match exceed historical publish earning annual general meeting earning share roche march trademark mention enjoy legal protection roche finance report publish german english case doubt difference interpretation english version shall prevail german text print nonchlorine bleach fsccertified paper roche annual report issue hoffmannla roche ltd basel group communicationse roche finance report hoffmannla roche ltd finance report basel switzerland trademark legally protect wwwrochecom